ricky1991 personal page - To The Moon

ricky1991

ricky1991

No personal profile

42Follow

0Followers

0Topic

0Badge

2022-02-05

$sofi

2022-02-05

Like pla

2022 Could be a Success or a Lost Opportunity for Novavax

2021-07-06

Like pls

MRIN Stock: Why Reddit Investors Are Sending Marin Software Higher Today

2021-06-30

Comment and like

3 Stocks I Would Avoid at All Costs

2021-06-28

Please like

US IPO Week Ahead: DiDi makes its billion-dollar debut in a 17 IPO week

2021-06-17

To the moon

Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology

2021-06-17

Like pla

Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress

2021-06-14

Pls like

Vaccine Stocks Slide After Novavax Shot Proves Highly Effective

2021-06-13

Like and comment

S&P ekes out gains to close languid week

2021-06-08

Pls comment and like

The second-half recovery is underway, and these are the top stocks to own, analysts say

2021-05-17

Like pls.

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3564454055125110","uuid":"3564454055125110","gmtCreate":1601377070829,"gmtModify":1620519679030,"name":"ricky1991","pinyin":"ricky1991","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","hatId":"ca_profile_frame_Lm11L6","hatName":"","vip":1,"status":2,"fanSize":0,"headSize":42,"tweetSize":13,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.07","exceedPercentage":"93.54%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.03","exceedPercentage":"93.94%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.03","exceedPercentage":"93.28%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":8,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":2,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9098167250,"gmtCreate":1644049860495,"gmtModify":1676533886439,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"$sofi&nbsp;","listText":"$sofi&nbsp;","text":"$sofi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098167250","isVote":1,"tweetType":1,"viewCount":133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098166985,"gmtCreate":1644047779575,"gmtModify":1676533886158,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"Like pla","listText":"Like pla","text":"Like pla","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098166985","repostId":"1130580421","repostType":4,"repost":{"id":"1130580421","pubTimestamp":1644040812,"share":"https://ttm.financial/m/news/1130580421?lang=&edition=fundamental","pubTime":"2022-02-05 14:00","market":"us","language":"en","title":"2022 Could be a Success or a Lost Opportunity for Novavax","url":"https://stock-news.laohu8.com/highlight/detail?id=1130580421","media":"InvestorPlace","summary":"Novavax can either generate a boost of sales or lose an opportunity in the industry of vaccines against coronavirus","content":"<html><head></head><body><p><b>Novavax, Inc</b>. (NASDAQ:<b><u>NVAX</u></b><u>)</u> has had a tough year with losses of approximately 68%. It has already declined about 37% year-to-date, as well. However, as of Feb. 3, 2022, the stock has a 5-day return of nearly 25%. This increased volatility in the stock price is primarily news-driven.</p><p>Novavax is trying to become active in the global industry of vaccines against the coronavirus to put an end to the pandemic so all of us can return to normal conditions at which social distancing will be a distant memory, along with wearing face masks.</p><p><b>Novavax Business News</b></p><p>The latest business news is that Novavax got conditional authorization in the U.K for its protein-based Covid-19 vaccine called Nuvaxovid. It is reported that “the U.K. has already ordered up to 60 million doses of Novavax’s vaccine.”</p><p>The company announced that it filed for authorization in the U.S. market in late Jan. 2022. Novavax has been granted provisional registration for its vaccine in Australia. Additionally, in South Korea, the Ministry of Food and Drug Safety has approved the firm’s vaccine. At the same time the “European Commission (EC) has granted Novavax conditional marketing authorization (CMA) for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.”</p><p>Novavax also submitted for emergency use authorization of its vaccine in South Africa.</p><p>A lot of this news is a catalyst for NVAX stock. The greatest impact on the stock probably would be U.S. market approval for Nuvaxovid. Investors waiting for further positive news are already building a bull case for Novavax.</p><p><b>Bullish Scenario for NVAX Stock</b></p><p>Novavax’s vaccine is the fifth vaccine approved by the E.U. Protein vaccines like Nuvaxovid can do a lot for the global vaccination campaign. This is because they work differently from the vaccines currently available in the E.U., which are based on either mRNA technology, such as Pfizer and Moderna, or viral vector technology, such as AstraZeneca and Johnson &amp; Johnson.</p><p>If unvaccinated people are not biased against vaccination to protect from Covid-19, they could soon be vaccinated with protein vaccines such as Nuvaxovid. Such protein vaccines have been used for decades to protect against polio, tetanus, hepatitis B, and the flu. They also offer very good protection against coronavirus and cause even fewer side effects than vaccines that are already approved.</p><p>Also, these vaccines are important. Richer countries are so preoccupied with booster vaccinations and closing vaccination gaps that they may forget that in poor countries very few people have been vaccinated.</p><p>Protein-based vaccines could also make a significant contribution to the market. They are relatively inexpensive to produce and can be transported and stored at 2° to 8° C much more easily than mRNA vaccines, which need to be frozen.</p><p>Novavax will first supply its vaccine in poorer countries like Africa. The Novavax vaccine is a combination vaccine that is said to protect against the coronavirus and the flu at the same time. According to Novavax, initially,100 million doses of the vaccine could be produced per month. They later expect to be able to produce 150 million doses of the vaccine per month.</p><p>Europe being supplied with Nuvaxovid is certainly big news for Novavax. The U.S. Food and Drug Administration (FDA) may become biased and send the green light for the biotechnology company to boost its sales, especially if its price is cheaper than other vaccines.</p><p><b>Bearish Case for NVAX Stock</b></p><p>Third quarter (Q3) 2021 financial results showed a year-over-year increase of 14% for revenue to $179 million and a 38% increase of total expenses to $486 million. Loss from operations widened to $307 million compared to a loss of $194 million in Q3 2020. Net loss also widened to $322 million compared to a net loss of $197 million in Q3 2020.</p><p>The firm has poor financial strength as the debt-to-equity (D/E) ratio of 0.70 is considered high for a money-losing business that has been burning cash over the past five consecutive years.</p><p>Another negative sign for NVAX stock is that shareholders have been substantially diluted in the past year, with total shares outstanding growing by 137.4%.</p><p><b>Novavax: At an Inflection Point Now</b></p><p>The company has positive news that sparks enthusiasm. The broader fundamental analysis, however, is not supportive of the company. Widening losses and burning cash must be addressed fast and radically for a stock price rebound to occur and last.</p><p>I remain bearish on NVAX stock, waiting for sales updates as the key catalyst.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Could be a Success or a Lost Opportunity for Novavax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Could be a Success or a Lost Opportunity for Novavax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 14:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/02/2022-could-be-a-success-or-a-lost-opportunity-for-novavax/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax, Inc. (NASDAQ:NVAX) has had a tough year with losses of approximately 68%. It has already declined about 37% year-to-date, as well. However, as of Feb. 3, 2022, the stock has a 5-day return of...</p>\n\n<a href=\"https://investorplace.com/2022/02/2022-could-be-a-success-or-a-lost-opportunity-for-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/02/2022-could-be-a-success-or-a-lost-opportunity-for-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130580421","content_text":"Novavax, Inc. (NASDAQ:NVAX) has had a tough year with losses of approximately 68%. It has already declined about 37% year-to-date, as well. However, as of Feb. 3, 2022, the stock has a 5-day return of nearly 25%. This increased volatility in the stock price is primarily news-driven.Novavax is trying to become active in the global industry of vaccines against the coronavirus to put an end to the pandemic so all of us can return to normal conditions at which social distancing will be a distant memory, along with wearing face masks.Novavax Business NewsThe latest business news is that Novavax got conditional authorization in the U.K for its protein-based Covid-19 vaccine called Nuvaxovid. It is reported that “the U.K. has already ordered up to 60 million doses of Novavax’s vaccine.”The company announced that it filed for authorization in the U.S. market in late Jan. 2022. Novavax has been granted provisional registration for its vaccine in Australia. Additionally, in South Korea, the Ministry of Food and Drug Safety has approved the firm’s vaccine. At the same time the “European Commission (EC) has granted Novavax conditional marketing authorization (CMA) for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.”Novavax also submitted for emergency use authorization of its vaccine in South Africa.A lot of this news is a catalyst for NVAX stock. The greatest impact on the stock probably would be U.S. market approval for Nuvaxovid. Investors waiting for further positive news are already building a bull case for Novavax.Bullish Scenario for NVAX StockNovavax’s vaccine is the fifth vaccine approved by the E.U. Protein vaccines like Nuvaxovid can do a lot for the global vaccination campaign. This is because they work differently from the vaccines currently available in the E.U., which are based on either mRNA technology, such as Pfizer and Moderna, or viral vector technology, such as AstraZeneca and Johnson & Johnson.If unvaccinated people are not biased against vaccination to protect from Covid-19, they could soon be vaccinated with protein vaccines such as Nuvaxovid. Such protein vaccines have been used for decades to protect against polio, tetanus, hepatitis B, and the flu. They also offer very good protection against coronavirus and cause even fewer side effects than vaccines that are already approved.Also, these vaccines are important. Richer countries are so preoccupied with booster vaccinations and closing vaccination gaps that they may forget that in poor countries very few people have been vaccinated.Protein-based vaccines could also make a significant contribution to the market. They are relatively inexpensive to produce and can be transported and stored at 2° to 8° C much more easily than mRNA vaccines, which need to be frozen.Novavax will first supply its vaccine in poorer countries like Africa. The Novavax vaccine is a combination vaccine that is said to protect against the coronavirus and the flu at the same time. According to Novavax, initially,100 million doses of the vaccine could be produced per month. They later expect to be able to produce 150 million doses of the vaccine per month.Europe being supplied with Nuvaxovid is certainly big news for Novavax. The U.S. Food and Drug Administration (FDA) may become biased and send the green light for the biotechnology company to boost its sales, especially if its price is cheaper than other vaccines.Bearish Case for NVAX StockThird quarter (Q3) 2021 financial results showed a year-over-year increase of 14% for revenue to $179 million and a 38% increase of total expenses to $486 million. Loss from operations widened to $307 million compared to a loss of $194 million in Q3 2020. Net loss also widened to $322 million compared to a net loss of $197 million in Q3 2020.The firm has poor financial strength as the debt-to-equity (D/E) ratio of 0.70 is considered high for a money-losing business that has been burning cash over the past five consecutive years.Another negative sign for NVAX stock is that shareholders have been substantially diluted in the past year, with total shares outstanding growing by 137.4%.Novavax: At an Inflection Point NowThe company has positive news that sparks enthusiasm. The broader fundamental analysis, however, is not supportive of the company. Widening losses and burning cash must be addressed fast and radically for a stock price rebound to occur and last.I remain bearish on NVAX stock, waiting for sales updates as the key catalyst.","news_type":1},"isVote":1,"tweetType":1,"viewCount":378,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":157275154,"gmtCreate":1625585773478,"gmtModify":1703744504571,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/157275154","repostId":"1142221624","repostType":4,"repost":{"id":"1142221624","pubTimestamp":1625585310,"share":"https://ttm.financial/m/news/1142221624?lang=&edition=fundamental","pubTime":"2021-07-06 23:28","market":"us","language":"en","title":"MRIN Stock: Why Reddit Investors Are Sending Marin Software Higher Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1142221624","media":"investorplace","summary":"Marin Software(NASDAQ:MRIN) stock is soaring higher on Tuesday as Reddit traders continue to pump up","content":"<p><b>Marin Software</b>(NASDAQ:<b><u>MRIN</u></b>) stock is soaring higher on Tuesday as Reddit traders continue to pump up the company’s shares.</p>\n<p>So why exactly are Reddit investors taking such a liking to MRIN stock today? There’s no recent news that would result in increasing interest from investors. That includes from inside or outside the company.</p>\n<p>Even if we head over to Reddit, it doesn’t look like those traders know why shares of MRIN stock are on the move today. Here’s a few examples of what users are saying.</p>\n<blockquote>\n <ul>\n  <li>“How the hell do i get in on meme stocks BEFORE they rocket?! Lol #MRIN” —thejet6969</li>\n  <li>“When y’all gon hop on MRIN?? That shit been flying under the radar with crazy volume and well over 100% short interest.” —chizbejoe</li>\n  <li>“Full on FOMO let’s go MRIN! Idk why, I’ll do my DD later. I like green crayons.” —amandarawrr</li>\n  <li>“Is there any solid reason why MRIN &amp; BLIN are flying or are they meme stocks now lol.” —friedchicken4health</li>\n </ul>\n</blockquote>\n<p>Even without any solid news sending MRIN stock higher today, there’s heavy trading of shares that investors should be aware of. As of this writing, more than 25 million shares of the stock have changed hands. That’s a major jump in morning volatility compared to the company’s daily average trading volume of about 20.6 million shares.</p>\n<p>MRIN stock was up 18.5% as of Tuesday morning and is up 1,109.6% since the start of the year.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MRIN Stock: Why Reddit Investors Are Sending Marin Software Higher Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMRIN Stock: Why Reddit Investors Are Sending Marin Software Higher Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 23:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/07/mrin-stock-why-reddit-investors-are-sending-marin-software-higher-today/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Marin Software(NASDAQ:MRIN) stock is soaring higher on Tuesday as Reddit traders continue to pump up the company’s shares.\nSo why exactly are Reddit investors taking such a liking to MRIN stock today?...</p>\n\n<a href=\"https://investorplace.com/2021/07/mrin-stock-why-reddit-investors-are-sending-marin-software-higher-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRIN":"Marin Software Inc."},"source_url":"https://investorplace.com/2021/07/mrin-stock-why-reddit-investors-are-sending-marin-software-higher-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142221624","content_text":"Marin Software(NASDAQ:MRIN) stock is soaring higher on Tuesday as Reddit traders continue to pump up the company’s shares.\nSo why exactly are Reddit investors taking such a liking to MRIN stock today? There’s no recent news that would result in increasing interest from investors. That includes from inside or outside the company.\nEven if we head over to Reddit, it doesn’t look like those traders know why shares of MRIN stock are on the move today. Here’s a few examples of what users are saying.\n\n\n“How the hell do i get in on meme stocks BEFORE they rocket?! Lol #MRIN” —thejet6969\n“When y’all gon hop on MRIN?? That shit been flying under the radar with crazy volume and well over 100% short interest.” —chizbejoe\n“Full on FOMO let’s go MRIN! Idk why, I’ll do my DD later. I like green crayons.” —amandarawrr\n“Is there any solid reason why MRIN & BLIN are flying or are they meme stocks now lol.” —friedchicken4health\n\n\nEven without any solid news sending MRIN stock higher today, there’s heavy trading of shares that investors should be aware of. As of this writing, more than 25 million shares of the stock have changed hands. That’s a major jump in morning volatility compared to the company’s daily average trading volume of about 20.6 million shares.\nMRIN stock was up 18.5% as of Tuesday morning and is up 1,109.6% since the start of the year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":421,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151189940,"gmtCreate":1625067450680,"gmtModify":1703735433736,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"Comment and like","listText":"Comment and like","text":"Comment and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/151189940","repostId":"2147146918","repostType":4,"repost":{"id":"2147146918","pubTimestamp":1625067140,"share":"https://ttm.financial/m/news/2147146918?lang=&edition=fundamental","pubTime":"2021-06-30 23:32","market":"us","language":"en","title":"3 Stocks I Would Avoid at All Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2147146918","media":"Motley Fool","summary":"These companies have set investors in their stocks up for disappointment.","content":"<p><b>AMC Entertainment Holdings </b>(NYSE:AMC), <b>GameStop </b>(NYSE:GME), and <b>Koss </b>(NASDAQ:KOSS) have become some of the more popular meme stocks in recent months. Traders monitoring Reddit's WallStreetBets online forum and other investors driven by social media have enjoyed some success trying to force short squeezes. But when the dust clears and momentum traders move on, investors could find themselves stuck holding stock in struggling companies with weak competitive advantages.</p>\n<p>Let's find out a bit more about why these are three stocks I would avoid at all costs.</p>\n<h2>1. AMC: Can it return to pre-pandemic revenue levels?</h2>\n<p>Thanks mainly to traders looking to force short sellers to cover their bets, AMC has risen nearly 2,700% since the beginning of the year. This outsized interest in the stock has made it possible for the international theater chain to issue additional shares and raise sorely needed funds.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F632064%2Fgettyimages-1162949169.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"399\"><span>Image source: Getty Images.</span></p>\n<p>Since Jan. 1, the overall share count has risen from 224 million to 502 million. This raised its cash levels by more than $500 million to $813 million in the first three months of the year.</p>\n<p>Nonetheless, the business continues to suffer. Revenue fell 84% in the first quarter of 2021 from year-ago levels and declined 77% during fiscal 2020 compared with 2019.</p>\n<p>Theater reopenings could bring revenue improvements when AMC releases its second-quarter results. But will they show enough improvement to reflect the massive surge in the stock price? Thanks to the run-up, the price-to-sales (P/S) ratio now stands at 25, up from 0.2 at the beginning of the year. Until the recent surge in the stock price, the sales multiple had rarely climbed above 0.5 over the last three years.</p>\n<p>Unfortunately, investors seem to have fewer reasons than ever to buy this stock at a high valuation. Hollywood studios have only recently started to release new films to theaters. And they now release many of them to streaming services simultaneously, dramatically increasing AMC's competition. Moreover, many consumers have built home theaters that replicate the theater experience.</p>\n<p>Yes, many moviegoers will probably still go to theaters despite these factors. However, reduced demand will bring about consolidation, making it more likely AMC and its peers will close some theaters. Thus, it remains unclear when or even if AMC will return to pre-pandemic revenue levels.</p>\n<h2>2. GameStop: New management and sales growth won't be enough</h2>\n<p>Thanks to a social media-inspired battle with the short-sellers, GameStop stock has managed to increase by more than 1,000% since the beginning of the year. Now, this video-game-centric retailer has just turned the corner by attracting institutional investors and joining the <b>Russell 1000</b>.</p>\n<p>It also has branched out into new lines of business, such as toys and collectibles. Nonetheless, investors have primarily focused on the move into e-commerce to capitalize on game downloads. To that end, it hired e-commerce specialist Matt Furlong as its new CEO. Furlong ran <b>Amazon</b>'s Australia operations during a period of high growth.</p>\n<p>Unfortunately, these moves might do little more than stop its competitive moat from narrowing further. Now, GameStop is merely another seller in the toy and collectible businesses. Moreover, its game downloads typically sell for the same price on the manufacturer's website. Besides serving as a <a href=\"https://laohu8.com/S/AONE\">one</a>-stop-shop for game downloads, it offers little advantage other than the name recognition it built in past years.</p>\n<p>Nonetheless, the improvements helped revenue to grow 25% from year-ago levels to $1.3 billion in the first quarter of 2021. Moreover, falling operating expenses helped narrow the quarterly loss to $67 million versus $166 million in the year-ago quarter. Still, net sales fell 21% in fiscal 2020.</p>\n<p>Furthermore, at a P/S ratio of 2.6, it might appear inexpensive. However, with that ratio growing by more than 4,500% over the last year, any progress it could make in the near term might already be priced in.</p>\n<h2>3. Koss: Struggling to gain market share in a crowded market</h2>\n<p>Koss has also enjoyed some notoriety as a meme stock, reaching a high of $127.45 per share in early January on speculation driven by social media, before a massive pullback. This headphone and audio accessory manufacturer now trades in the $25-per-share range.</p>\n<p>After decades of struggling for survival, the company has won praise in recent years in the headset market. Many of its Bluetooth and wireless headsets earned ratings close to five stars on Amazon.</p>\n<p>Unfortunately, its products continue to operate at a competitive disadvantage. Koss must also compete with companies such as <b>Apple </b>and <b>Sony</b>. Aside from their massive size and name-recognition advantages, both operate ecosystems that could give their headsets an advantage. Moreover, a survey by CSIMarket found Koss' headsets held a market share of less than 1%.</p>\n<p>This disadvantage extends to financials. For the first nine months of the current fiscal year, sales fell 2% from the year-ago period. Koss managed to reverse the losses suffered during 2020 and posted a profit of almost $162,000 during that time.</p>\n<p>However, the forgiveness of a $507,000 Small Business Administration loan and a $379,000 gain from the settlement of a short sale drove the positive net income. Otherwise, Koss would have lost $724,000 during that period, more than the $624,000 loss from the first nine months of 2020.</p>\n<p>Moreover, it has reported about $982,000 in negative cash flows during the current fiscal year and holds just over $6 million in cash. Given that financial state, it may struggle to finance the marketing and product improvements necessary to keep up with larger competitors.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks I Would Avoid at All Costs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks I Would Avoid at All Costs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 23:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/30/3-stocks-i-would-avoid-at-all-costs/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AMC Entertainment Holdings (NYSE:AMC), GameStop (NYSE:GME), and Koss (NASDAQ:KOSS) have become some of the more popular meme stocks in recent months. Traders monitoring Reddit's WallStreetBets online ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/30/3-stocks-i-would-avoid-at-all-costs/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线","GME":"游戏驿站","KOSS":"高斯电子"},"source_url":"https://www.fool.com/investing/2021/06/30/3-stocks-i-would-avoid-at-all-costs/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147146918","content_text":"AMC Entertainment Holdings (NYSE:AMC), GameStop (NYSE:GME), and Koss (NASDAQ:KOSS) have become some of the more popular meme stocks in recent months. Traders monitoring Reddit's WallStreetBets online forum and other investors driven by social media have enjoyed some success trying to force short squeezes. But when the dust clears and momentum traders move on, investors could find themselves stuck holding stock in struggling companies with weak competitive advantages.\nLet's find out a bit more about why these are three stocks I would avoid at all costs.\n1. AMC: Can it return to pre-pandemic revenue levels?\nThanks mainly to traders looking to force short sellers to cover their bets, AMC has risen nearly 2,700% since the beginning of the year. This outsized interest in the stock has made it possible for the international theater chain to issue additional shares and raise sorely needed funds.\nImage source: Getty Images.\nSince Jan. 1, the overall share count has risen from 224 million to 502 million. This raised its cash levels by more than $500 million to $813 million in the first three months of the year.\nNonetheless, the business continues to suffer. Revenue fell 84% in the first quarter of 2021 from year-ago levels and declined 77% during fiscal 2020 compared with 2019.\nTheater reopenings could bring revenue improvements when AMC releases its second-quarter results. But will they show enough improvement to reflect the massive surge in the stock price? Thanks to the run-up, the price-to-sales (P/S) ratio now stands at 25, up from 0.2 at the beginning of the year. Until the recent surge in the stock price, the sales multiple had rarely climbed above 0.5 over the last three years.\nUnfortunately, investors seem to have fewer reasons than ever to buy this stock at a high valuation. Hollywood studios have only recently started to release new films to theaters. And they now release many of them to streaming services simultaneously, dramatically increasing AMC's competition. Moreover, many consumers have built home theaters that replicate the theater experience.\nYes, many moviegoers will probably still go to theaters despite these factors. However, reduced demand will bring about consolidation, making it more likely AMC and its peers will close some theaters. Thus, it remains unclear when or even if AMC will return to pre-pandemic revenue levels.\n2. GameStop: New management and sales growth won't be enough\nThanks to a social media-inspired battle with the short-sellers, GameStop stock has managed to increase by more than 1,000% since the beginning of the year. Now, this video-game-centric retailer has just turned the corner by attracting institutional investors and joining the Russell 1000.\nIt also has branched out into new lines of business, such as toys and collectibles. Nonetheless, investors have primarily focused on the move into e-commerce to capitalize on game downloads. To that end, it hired e-commerce specialist Matt Furlong as its new CEO. Furlong ran Amazon's Australia operations during a period of high growth.\nUnfortunately, these moves might do little more than stop its competitive moat from narrowing further. Now, GameStop is merely another seller in the toy and collectible businesses. Moreover, its game downloads typically sell for the same price on the manufacturer's website. Besides serving as a one-stop-shop for game downloads, it offers little advantage other than the name recognition it built in past years.\nNonetheless, the improvements helped revenue to grow 25% from year-ago levels to $1.3 billion in the first quarter of 2021. Moreover, falling operating expenses helped narrow the quarterly loss to $67 million versus $166 million in the year-ago quarter. Still, net sales fell 21% in fiscal 2020.\nFurthermore, at a P/S ratio of 2.6, it might appear inexpensive. However, with that ratio growing by more than 4,500% over the last year, any progress it could make in the near term might already be priced in.\n3. Koss: Struggling to gain market share in a crowded market\nKoss has also enjoyed some notoriety as a meme stock, reaching a high of $127.45 per share in early January on speculation driven by social media, before a massive pullback. This headphone and audio accessory manufacturer now trades in the $25-per-share range.\nAfter decades of struggling for survival, the company has won praise in recent years in the headset market. Many of its Bluetooth and wireless headsets earned ratings close to five stars on Amazon.\nUnfortunately, its products continue to operate at a competitive disadvantage. Koss must also compete with companies such as Apple and Sony. Aside from their massive size and name-recognition advantages, both operate ecosystems that could give their headsets an advantage. Moreover, a survey by CSIMarket found Koss' headsets held a market share of less than 1%.\nThis disadvantage extends to financials. For the first nine months of the current fiscal year, sales fell 2% from the year-ago period. Koss managed to reverse the losses suffered during 2020 and posted a profit of almost $162,000 during that time.\nHowever, the forgiveness of a $507,000 Small Business Administration loan and a $379,000 gain from the settlement of a short sale drove the positive net income. Otherwise, Koss would have lost $724,000 during that period, more than the $624,000 loss from the first nine months of 2020.\nMoreover, it has reported about $982,000 in negative cash flows during the current fiscal year and holds just over $6 million in cash. Given that financial state, it may struggle to finance the marketing and product improvements necessary to keep up with larger competitors.","news_type":1},"isVote":1,"tweetType":1,"viewCount":325,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150356654,"gmtCreate":1624888195278,"gmtModify":1703847100780,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150356654","repostId":"1150095060","repostType":4,"repost":{"id":"1150095060","pubTimestamp":1624874134,"share":"https://ttm.financial/m/news/1150095060?lang=&edition=fundamental","pubTime":"2021-06-28 17:55","market":"us","language":"en","title":"US IPO Week Ahead: DiDi makes its billion-dollar debut in a 17 IPO week","url":"https://stock-news.laohu8.com/highlight/detail?id=1150095060","media":"Renaissance Capital","summary":"17 IPOs are slated to raise $9.1 billion in this week, led by long-awaited Chinese ride-hailing giant $DiDi Global Inc.$.DiDi plans to raise $3.9 billion at a $67.5 billion market cap. DiDi is China’s dominant ride-hailing app, with 15 million drivers across 4,000 cities and towns. The unprofitable company saw revenue more than double in the 1Q21 as its business recovered post-pandemic.New and existing investors intend to purchase $1.3 billion of the IPO.Cybersecurity platform $SentinelOne, Inc$","content":"<p>17 IPOs are slated to raise $9.1 billion in this week, led by long-awaited Chinese ride-hailing giant<b>&nbsp;<a href=\"https://laohu8.com/S/DIDI\">DiDi Global Inc.</a>.</b></p>\n<p><b>DiDi</b>&nbsp;plans to raise $3.9 billion at a $67.5 billion market cap. DiDi is China’s dominant ride-hailing app, with 15 million drivers across 4,000 cities and towns. The unprofitable company saw revenue more than double in the 1Q21 as its business recovered post-pandemic.New and existing investors intend to purchase $1.3 billion of the IPO.</p>\n<p>Cybersecurity platform&nbsp;<b><a href=\"https://laohu8.com/S/S\">SentinelOne, Inc</a></b> plans to raise $880 million at an $8.2 billion market cap. SentinelOne's Singularity Platform is an AI-powered extended detection and response platform that ingests, correlates and queries petabytes of structured and unstructured data to provide autonomous cybersecurity defense. Fast growing and unprofitable, the company had over 4,700 customers as of 4/30/21, up from 2,700 a year prior.</p>\n<p>Turkish e-commerce platform&nbsp;<b>D-MARKET Electronic Services &amp; Trading</b>(HEPS) plans to raise $681 million at a $3.9 billion market cap. Operating under the name Hepsiburada, the company connected 33 million members, 9 million Active Customers, and a base of approximately 45 thousand Active Merchants in 2020. The company is fast growing but EBITDA swung negative in the 1Q21.</p>\n<p>Doughnut brand&nbsp;<a href=\"https://laohu8.com/S/DNUT\"><b>Krispy Kreme, Inc.</a> </b>plans to raise $600 million at a $3.8 billion market cap. Krispy Kreme is an omni-channel business operating through a network of doughnut shops, partnerships with retailers, and an e-Commerce and delivery business. The company has a long track record and strong brand awareness, though its growth strategy is unproven.</p>\n<p>Legal solutions provider&nbsp;<b><a href=\"https://laohu8.com/S/LZ\">LegalZoom.com, Inc</a> </b>plans to raise $488 million at a $5.3 billion market cap. LegalZoom states that it is a leading online platform for legal and compliance solutions, claiming that 10% of new LLCs and 5% of new corporations in the US were formed via LegalZoom in 2020. Profitable on an EBITDA basis in the 1Q21, the company operates across all 50 states and over 3,000 counties in the US.</p>\n<p>Identity verification platform&nbsp;<b><a href=\"https://laohu8.com/S/YOU\">Clear Secure, Inc.</a></b> plans to raise $376 million at a $4.1 billion market cap. Clear Secure's secure identity platform uses to automate the identity verification process, with main offerings including CLEAR Plus, a consumer aviation subscription service, and two mobile apps. As of 5/31/21, Clear Secure's network included 38 airports, 26 sports and entertainment partners, and 67 Health Pass-enabled partners.</p>\n<p>Chinese grocery delivery platform&nbsp;<b><a href=\"https://laohu8.com/S/DDL\">Dingdong (Cayman) Limited</a> </b>plans to raise $343 million at a $6.0 billion market cap. With fresh groceries as its core product categories, Dingdong states that it is the fastest growing on-demand e-commerce company in China. Unprofitable with explosive growth, the company had a 10% share of the on-demand e-commerce market by GMV in 2020.</p>\n<p>SaaS solutions provider&nbsp;<b><a href=\"https://laohu8.com/S/EVCM\">EverCommerce Inc.</a></b> plans to raise $325 million at a $3.4 billion market cap. EverCommerce is a leading provider of integrated, vertically-tailored SaaS solutions for service-based SMBs. The company serves over 500,000 customers across three core verticals: Home Services, Health Services, and Fitness &amp; Wellness Services.</p>\n<p>Software provider&nbsp;<b><a href=\"https://laohu8.com/S/INTA\">Intapp, Inc.</a> </b>plans to raise $278 million at a $1.9 billion market cap. Intapp provides industry-specific, cloud-based software solutions for the professional and financial services industry globally. The company had over 1,600 clients as of March 31, 2021, and it currently has more than 20 clients with contracts greater than $1 million of ARR.</p>\n<p>Online manufacturing marketplace&nbsp;<b><a href=\"https://laohu8.com/S/XMTR\">Xometry, Inc.</a></b> plans to raise $275 million at a $1.9 billion market cap. Xometry states that it is a leading AI-enabled marketplace for on-demand manufacturing. Its buyers include businesses ranging from self-funded start-ups to Fortune 100 companies. Since its inception, over 6.0 million parts have been manufactured through Xometry's platform.</p>\n<p><b><a href=\"https://laohu8.com/S/IAS\">Integral Ad Science Holding LLC</a> </b>plans to raise $240 million at a $2.5 billion market cap. The company’s technology provides metrics designed to verify that digital ads are served to a real person, viewable on-screen, and appear in a brand-safe and suitable environment in the correct geography. Profitable on an EBIT basis, Integral Ad Science served over 2,000 customers as of 3/31/21.</p>\n<p>Plus-sized women’s apparel brand&nbsp;<b><a href=\"https://laohu8.com/S/CURV\">Torrid Holdings</a> </b>plans to raise $156 million at a $2.1 billion market cap. Torrid is the largest direct-to-consumer brand of women's plus-size apparel and intimates in North America by net sales. The profitable company markets directly to consumers via physical stores and its e-commerce platform, which represented a majority of sales in the 12 months ended 5/1/21.</p>\n<p>Alzheimer’s biotech&nbsp;<b><a href=\"https://laohu8.com/S/ABOS\">Acumen Pharmaceuticals, Inc.</a></b> plans to raise $125 million at a $607 million market cap. The company's lead candidate, ACU193, is a humanized monoclonal antibody that selectively targets amyloid-beta oligomers. ACU193 entered a Phase 1 trial in patients with mild dementia or cognitive impairment due to AD in the 2Q21, with data expected by year end 2022.</p>\n<p>Digital financial services provider&nbsp;<b>AMTD Digital</b>(<a href=\"https://laohu8.com/S/HKD\">$(HKD)$</a>) plans to raise $120 million at a $1.4 billion market cap. AMTD Digital states that it is the \"fusion reactor\" at the core of the AMTD SpiderNet ecosystem, operating a comprehensive digital solutions platform in Asia. Profitable with explosive growth, the company primarily generates revenue from fees and commissions in two lines of business.</p>\n<p>Drug formulation developer&nbsp;<b>Aerovate Therapeutics</b>(<a href=\"https://laohu8.com/S/AVTE\">$(AVTE)$</a>) plans to raise $100 million at a $325 million market cap. Aerovate's initial focus is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH). The company has completed a Phase 1 study in healthy volunteers and expects to begin a Phase 2b/3 trial in PAH patients in the 2H21.</p>\n<p>Neuromodulation device provider<b>&nbsp;<a href=\"https://laohu8.com/S/CVRX\">CVRx Inc</a> </b>plans to raise $100 million at a $333 million market cap. CVRx manufactures and markets its minimally invasive neuromodulation solutions on its proprietary BAROSTIM platform. The company's states that its BAROSTEM NEO product is the first and only commercially available neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction.</p>\n<p>Belgium-listed&nbsp;<b>Nyxoah</b>(<a href=\"https://laohu8.com/S/NYXH\">$(NYXH)$</a>) plans to raise $87 million at an $803 million market cap. Nyxoah's lead product is the Genio system, a CE-marked, minimally-invasive hypoglossal neurostimulation therapy for obstructive sleep apnea. The company began generating revenue from Genio in Europe in July 2020 and is currently conducting a pivotal trial designed to support marketing authorization in the US.</p>\n<p><img src=\"https://static.tigerbbs.com/58f28d5f7f3b8e686c0bd006c2968b99\" tg-width=\"1131\" tg-height=\"684\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/508f1118f1d92b2b76391bc3610bd6c4\" tg-width=\"1131\" tg-height=\"657\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/ed04cd42fa30b460fcf67e07efa6ddc7\" tg-width=\"1130\" tg-height=\"166\" referrerpolicy=\"no-referrer\"></p>\n<p><b>IPO Market Snapshot</b></p>\n<p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 6/24/21, the Renaissance IPO Index was up 2.7% year-to-date, while the S&amp;P 500 was up 13.6%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Palantir Technologies (PLTR). The Renaissance International IPO Index was down 1.5% year-to-date, while the ACWX was up 10.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Smoore International and EQT Partners.</p>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: DiDi makes its billion-dollar debut in a 17 IPO week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: DiDi makes its billion-dollar debut in a 17 IPO week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-28 17:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/83318/US-IPO-Week-Ahead-DiDi-makes-its-billion-dollar-debut-in-a-17-IPO-week><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>17 IPOs are slated to raise $9.1 billion in this week, led by long-awaited Chinese ride-hailing giant DiDi Global Inc..\nDiDi plans to raise $3.9 billion at a $67.5 billion market cap. DiDi is China’s ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/83318/US-IPO-Week-Ahead-DiDi-makes-its-billion-dollar-debut-in-a-17-IPO-week\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABOS":"Acumen Pharmaceuticals, Inc.","HEPS":"D-MARKET Electronic Services & Trading","CVRX":"CVRx, Inc.","S":"SentinelOne, Inc","LZ":"LegalZoom.com, Inc","IAS":"Integral Ad Science Holding","INTA":"Intapp, Inc.","YOU":"Clear Secure, Inc.","XMTR":"Xometry, Inc.","EVCM":"EverCommerce Inc.","DNUT":"Krispy Kreme, Inc.","CURV":"Torrid Holdings","DIDI":"滴滴(已退市)","DDL":"叮咚买菜"},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/83318/US-IPO-Week-Ahead-DiDi-makes-its-billion-dollar-debut-in-a-17-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150095060","content_text":"17 IPOs are slated to raise $9.1 billion in this week, led by long-awaited Chinese ride-hailing giant DiDi Global Inc..\nDiDi plans to raise $3.9 billion at a $67.5 billion market cap. DiDi is China’s dominant ride-hailing app, with 15 million drivers across 4,000 cities and towns. The unprofitable company saw revenue more than double in the 1Q21 as its business recovered post-pandemic.New and existing investors intend to purchase $1.3 billion of the IPO.\nCybersecurity platform SentinelOne, Inc plans to raise $880 million at an $8.2 billion market cap. SentinelOne's Singularity Platform is an AI-powered extended detection and response platform that ingests, correlates and queries petabytes of structured and unstructured data to provide autonomous cybersecurity defense. Fast growing and unprofitable, the company had over 4,700 customers as of 4/30/21, up from 2,700 a year prior.\nTurkish e-commerce platform D-MARKET Electronic Services & Trading(HEPS) plans to raise $681 million at a $3.9 billion market cap. Operating under the name Hepsiburada, the company connected 33 million members, 9 million Active Customers, and a base of approximately 45 thousand Active Merchants in 2020. The company is fast growing but EBITDA swung negative in the 1Q21.\nDoughnut brand Krispy Kreme, Inc. plans to raise $600 million at a $3.8 billion market cap. Krispy Kreme is an omni-channel business operating through a network of doughnut shops, partnerships with retailers, and an e-Commerce and delivery business. The company has a long track record and strong brand awareness, though its growth strategy is unproven.\nLegal solutions provider LegalZoom.com, Inc plans to raise $488 million at a $5.3 billion market cap. LegalZoom states that it is a leading online platform for legal and compliance solutions, claiming that 10% of new LLCs and 5% of new corporations in the US were formed via LegalZoom in 2020. Profitable on an EBITDA basis in the 1Q21, the company operates across all 50 states and over 3,000 counties in the US.\nIdentity verification platform Clear Secure, Inc. plans to raise $376 million at a $4.1 billion market cap. Clear Secure's secure identity platform uses to automate the identity verification process, with main offerings including CLEAR Plus, a consumer aviation subscription service, and two mobile apps. As of 5/31/21, Clear Secure's network included 38 airports, 26 sports and entertainment partners, and 67 Health Pass-enabled partners.\nChinese grocery delivery platform Dingdong (Cayman) Limited plans to raise $343 million at a $6.0 billion market cap. With fresh groceries as its core product categories, Dingdong states that it is the fastest growing on-demand e-commerce company in China. Unprofitable with explosive growth, the company had a 10% share of the on-demand e-commerce market by GMV in 2020.\nSaaS solutions provider EverCommerce Inc. plans to raise $325 million at a $3.4 billion market cap. EverCommerce is a leading provider of integrated, vertically-tailored SaaS solutions for service-based SMBs. The company serves over 500,000 customers across three core verticals: Home Services, Health Services, and Fitness & Wellness Services.\nSoftware provider Intapp, Inc. plans to raise $278 million at a $1.9 billion market cap. Intapp provides industry-specific, cloud-based software solutions for the professional and financial services industry globally. The company had over 1,600 clients as of March 31, 2021, and it currently has more than 20 clients with contracts greater than $1 million of ARR.\nOnline manufacturing marketplace Xometry, Inc. plans to raise $275 million at a $1.9 billion market cap. Xometry states that it is a leading AI-enabled marketplace for on-demand manufacturing. Its buyers include businesses ranging from self-funded start-ups to Fortune 100 companies. Since its inception, over 6.0 million parts have been manufactured through Xometry's platform.\nIntegral Ad Science Holding LLC plans to raise $240 million at a $2.5 billion market cap. The company’s technology provides metrics designed to verify that digital ads are served to a real person, viewable on-screen, and appear in a brand-safe and suitable environment in the correct geography. Profitable on an EBIT basis, Integral Ad Science served over 2,000 customers as of 3/31/21.\nPlus-sized women’s apparel brand Torrid Holdings plans to raise $156 million at a $2.1 billion market cap. Torrid is the largest direct-to-consumer brand of women's plus-size apparel and intimates in North America by net sales. The profitable company markets directly to consumers via physical stores and its e-commerce platform, which represented a majority of sales in the 12 months ended 5/1/21.\nAlzheimer’s biotech Acumen Pharmaceuticals, Inc. plans to raise $125 million at a $607 million market cap. The company's lead candidate, ACU193, is a humanized monoclonal antibody that selectively targets amyloid-beta oligomers. ACU193 entered a Phase 1 trial in patients with mild dementia or cognitive impairment due to AD in the 2Q21, with data expected by year end 2022.\nDigital financial services provider AMTD Digital($(HKD)$) plans to raise $120 million at a $1.4 billion market cap. AMTD Digital states that it is the \"fusion reactor\" at the core of the AMTD SpiderNet ecosystem, operating a comprehensive digital solutions platform in Asia. Profitable with explosive growth, the company primarily generates revenue from fees and commissions in two lines of business.\nDrug formulation developer Aerovate Therapeutics($(AVTE)$) plans to raise $100 million at a $325 million market cap. Aerovate's initial focus is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH). The company has completed a Phase 1 study in healthy volunteers and expects to begin a Phase 2b/3 trial in PAH patients in the 2H21.\nNeuromodulation device provider CVRx Inc plans to raise $100 million at a $333 million market cap. CVRx manufactures and markets its minimally invasive neuromodulation solutions on its proprietary BAROSTIM platform. The company's states that its BAROSTEM NEO product is the first and only commercially available neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction.\nBelgium-listed Nyxoah($(NYXH)$) plans to raise $87 million at an $803 million market cap. Nyxoah's lead product is the Genio system, a CE-marked, minimally-invasive hypoglossal neurostimulation therapy for obstructive sleep apnea. The company began generating revenue from Genio in Europe in July 2020 and is currently conducting a pivotal trial designed to support marketing authorization in the US.\n\nIPO Market Snapshot\nThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 6/24/21, the Renaissance IPO Index was up 2.7% year-to-date, while the S&P 500 was up 13.6%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Palantir Technologies (PLTR). The Renaissance International IPO Index was down 1.5% year-to-date, while the ACWX was up 10.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Smoore International and EQT Partners.","news_type":1},"isVote":1,"tweetType":1,"viewCount":316,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161747567,"gmtCreate":1623941963459,"gmtModify":1703824210706,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/161747567","repostId":"1199020816","repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"tweetType":1,"viewCount":364,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161748113,"gmtCreate":1623941812032,"gmtModify":1703824202103,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"Like pla","listText":"Like pla","text":"Like pla","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/161748113","repostId":"1179547045","repostType":4,"repost":{"id":"1179547045","pubTimestamp":1623941450,"share":"https://ttm.financial/m/news/1179547045?lang=&edition=fundamental","pubTime":"2021-06-17 22:50","market":"us","language":"en","title":"Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1179547045","media":"thestreet","summary":"Shares of Clearside Biomedical(CLSD)  jumped on Thursday after analysts at Wedbush tripled their pri","content":"<p>Shares of Clearside Biomedical(<b>CLSD</b>) &nbsp;jumped on Thursday after analysts at Wedbush tripled their price target for the company following positive data from the early stage eye treatment study.</p>\n<p>Wedbush analyst Liana Moussatos rates the stock outperform and tripled her price target to $18 a share.</p>\n<p>\"We find these initial results encouraging by first establishing a clear foundation of safety,\" Moussatos said.</p>\n<p>Shares of Clearside Biomedical at last check jumped 36% to $5.53. The shares on Thursday have traded at a 52-week high $5.66, up 39%. And they've bounced off a 52-week low $1.25, touched at the end of October.</p>\n<p>Clearside shares have been volatile, falling as low as $2.24 per share in late March. But since the calendar flipped to June, the stock as jumped more than 50%, including Thursday's jump.</p>\n<p>Earlier this week the company&nbsp;reported progress in a clinical trial of CLS-AX, a drug for pretreated wet age-related macular degeneration.</p>\n<p>Clearside said the initial lowest planned dose of 0.03 mg CLS-AX was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed throughout the study.</p>\n<p>The company said the improvements were reflected in the BCVA score, or best corrected visual acuity, with five of six patients each gaining four or more letters.</p>\n<p>Earlier this week the results prompted an analyst to call the treatment \"a game changer.\" Roth Capital analyst Zegbeh Jallah reiterated a buy rating and $9 price target on Clearside after the company reported data from the study.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/clearside-biomedical-stock-jumps-on-wedbush-upgrade><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Clearside Biomedical(CLSD)  jumped on Thursday after analysts at Wedbush tripled their price target for the company following positive data from the early stage eye treatment study.\nWedbush ...</p>\n\n<a href=\"https://www.thestreet.com/investing/clearside-biomedical-stock-jumps-on-wedbush-upgrade\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLSD":"Clearside Biomedical Inc."},"source_url":"https://www.thestreet.com/investing/clearside-biomedical-stock-jumps-on-wedbush-upgrade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1179547045","content_text":"Shares of Clearside Biomedical(CLSD)  jumped on Thursday after analysts at Wedbush tripled their price target for the company following positive data from the early stage eye treatment study.\nWedbush analyst Liana Moussatos rates the stock outperform and tripled her price target to $18 a share.\n\"We find these initial results encouraging by first establishing a clear foundation of safety,\" Moussatos said.\nShares of Clearside Biomedical at last check jumped 36% to $5.53. The shares on Thursday have traded at a 52-week high $5.66, up 39%. And they've bounced off a 52-week low $1.25, touched at the end of October.\nClearside shares have been volatile, falling as low as $2.24 per share in late March. But since the calendar flipped to June, the stock as jumped more than 50%, including Thursday's jump.\nEarlier this week the company reported progress in a clinical trial of CLS-AX, a drug for pretreated wet age-related macular degeneration.\nClearside said the initial lowest planned dose of 0.03 mg CLS-AX was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed throughout the study.\nThe company said the improvements were reflected in the BCVA score, or best corrected visual acuity, with five of six patients each gaining four or more letters.\nEarlier this week the results prompted an analyst to call the treatment \"a game changer.\" Roth Capital analyst Zegbeh Jallah reiterated a buy rating and $9 price target on Clearside after the company reported data from the study.","news_type":1},"isVote":1,"tweetType":1,"viewCount":356,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184345242,"gmtCreate":1623686362986,"gmtModify":1704208772007,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/184345242","repostId":"2143738859","repostType":4,"repost":{"id":"2143738859","pubTimestamp":1623684317,"share":"https://ttm.financial/m/news/2143738859?lang=&edition=fundamental","pubTime":"2021-06-14 23:25","market":"us","language":"en","title":"Vaccine Stocks Slide After Novavax Shot Proves Highly Effective","url":"https://stock-news.laohu8.com/highlight/detail?id=2143738859","media":"Bloomberg","summary":"(Bloomberg) -- The world’s top makers of Covid-19 vaccines are dropping after tests of Novavax Inc.’","content":"<p>(Bloomberg) -- The world’s top makers of Covid-19 vaccines are dropping after tests of Novavax Inc.’s shots showed they were 90% effective at preventing symptoms.</p>\n<p>Stocks tied to inoculations already cleared for emergency use fell in Monday’s trading, led by Moderna Inc.’s slide of as much as 9.5%. Pfizer Inc. fell 1.6% and the drugmaker’s German partner <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> dropped 6.1%. Even the consumer giant Johnson &amp; Johnson slipped 0.6%, slightly more than the S&amp;P 500 index as the broader market dropped back from Friday’s record highs.</p>\n<p>Novavax itself wasn’t immune from the downdraft it created, with the stock reversing a 9.5% gain on Monday to fall about 1%. The shot’s efficacy was better than Wall Street was expecting amid the spread of more resistant variants, and that’s raising the specter of new competition. Novavax now has “a viable alternative to mRNA vaccines,” like Pfizer and BioNTech or Moderna’s shots, an analyst at Jefferies said.</p>\n<p>But with Novavax up 91% so far this year and after a more than 2,700% leap in 2020, it wasn’t enough to further bolster shares. Biotech stocks often climb ahead of highly watched catalyst, only to give back gains even after a positive update.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Stocks Slide After Novavax Shot Proves Highly Effective</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Stocks Slide After Novavax Shot Proves Highly Effective\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 23:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/vaccine-stocks-slide-novavax-shot-145617752.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- The world’s top makers of Covid-19 vaccines are dropping after tests of Novavax Inc.’s shots showed they were 90% effective at preventing symptoms.\nStocks tied to inoculations already ...</p>\n\n<a href=\"https://finance.yahoo.com/news/vaccine-stocks-slide-novavax-shot-145617752.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc.","PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/vaccine-stocks-slide-novavax-shot-145617752.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143738859","content_text":"(Bloomberg) -- The world’s top makers of Covid-19 vaccines are dropping after tests of Novavax Inc.’s shots showed they were 90% effective at preventing symptoms.\nStocks tied to inoculations already cleared for emergency use fell in Monday’s trading, led by Moderna Inc.’s slide of as much as 9.5%. Pfizer Inc. fell 1.6% and the drugmaker’s German partner BioNTech SE dropped 6.1%. Even the consumer giant Johnson & Johnson slipped 0.6%, slightly more than the S&P 500 index as the broader market dropped back from Friday’s record highs.\nNovavax itself wasn’t immune from the downdraft it created, with the stock reversing a 9.5% gain on Monday to fall about 1%. The shot’s efficacy was better than Wall Street was expecting amid the spread of more resistant variants, and that’s raising the specter of new competition. Novavax now has “a viable alternative to mRNA vaccines,” like Pfizer and BioNTech or Moderna’s shots, an analyst at Jefferies said.\nBut with Novavax up 91% so far this year and after a more than 2,700% leap in 2020, it wasn’t enough to further bolster shares. Biotech stocks often climb ahead of highly watched catalyst, only to give back gains even after a positive update.","news_type":1},"isVote":1,"tweetType":1,"viewCount":279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182232851,"gmtCreate":1623576180373,"gmtModify":1704206510910,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"Like and comment&nbsp;","listText":"Like and comment&nbsp;","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/182232851","repostId":"2142204074","repostType":4,"repost":{"id":"2142204074","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623441637,"share":"https://ttm.financial/m/news/2142204074?lang=&edition=fundamental","pubTime":"2021-06-12 04:00","market":"us","language":"en","title":"S&P ekes out gains to close languid week","url":"https://stock-news.laohu8.com/highlight/detail?id=2142204074","media":"Reuters","summary":"NEW YORK, June 11  - The S&P 500 closed nominally higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.Economically sensitive smallcaps and transports notched solid gains, outperforming the broader market.For the week, the S&P and the Nasdaq advanced from last Friday's close, while the Dow posted a weekly loss.But th","content":"<p>NEW YORK, June 11 (Reuters) - The S&amp;P 500 closed nominally higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.</p>\n<p>Economically sensitive smallcaps and transports&nbsp;notched solid gains, outperforming the broader market.</p>\n<p>For the week, the S&amp;P and the Nasdaq advanced from last Friday's close, while the Dow posted a weekly loss.</p>\n<p>But the indexes have been range-bound, with few catalysts to move investor sentiment. Much of the focus centered on Thursday's consumer price data, which eased jitters over the duration of the current inflation wave.</p>\n<p>\"It’s a muted day today,\" Oliver Pursche, senior vice president at Wealthspire Advisors, in New York. \"The summer is settling in, people are slipping out of work early and there’s nothing in the news that’s going to materially drive the market in either direction.\"</p>\n<p>\"So, investors are going to wait until earnings season.\"</p>\n<p>The Federal Reserve has repeatedly said that near-term price surges will not metastasize into lasting inflation, an assertion reflected in the University of Michigan's Consumer Sentiment report released on Friday, which showed inflation expectations easing from last month's spike.</p>\n<p>Investors now turn their attention to the Fed's statement at the conclusion of next week's two-day monetary policy meeting, which will be parsed for clues regarding the central bank's timetable for raising key interest rates.</p>\n<p>\"Our view continues to be that inflationary data is transient and we will be around the 2% mark for the year,\" Pursche added.</p>\n<p>Benchmark U.S. Treasury yields posted their biggest weekly drop in nearly a year, weighing on the interest-sensitive financial sector in recent sessions.</p>\n<p>The Food and Drug Administration is facing mounting criticism over its \"accelerated approval\" of Biogen Inc's</p>\n<p>Alzheimer's drug Aduhelm without strong evidence of its ability to combat the disease.</p>\n<p>Biogen shares, along with the broader healthcare sector&nbsp;ended the session lower.</p>\n<p>Unofficially, the Dow Jones Industrial Average rose 14.41 points, or 0.04%, to 34,480.65, the S&amp;P 500 gained 8.29 points, or 0.20%, to 4,247.47 and the Nasdaq Composite&nbsp;added 49.09 points, or 0.35%, to 14,069.42.</p>\n<p>Among the 11 major sectors in the S&amp;P 500, healthcare suffered the biggest percentage drop.</p>\n<p>Much of the trading volume this week was attributable to the ongoing social media-driven \"meme stock\" phenomenon, in which retail investors swarm around heavily shorted stocks.</p>\n<p>But meme stock moves were more muted on Friday, with AMC Entertainment outperforming.</p>\n<p>(Reporting by Stephen Culp in New York Additional reporting by Ambar Warrick and Devik Jain in Bengaluru Editing by Matthew Lewis and Cynthia Osterman)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P ekes out gains to close languid week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P ekes out gains to close languid week\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-12 04:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, June 11 (Reuters) - The S&amp;P 500 closed nominally higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.</p>\n<p>Economically sensitive smallcaps and transports&nbsp;notched solid gains, outperforming the broader market.</p>\n<p>For the week, the S&amp;P and the Nasdaq advanced from last Friday's close, while the Dow posted a weekly loss.</p>\n<p>But the indexes have been range-bound, with few catalysts to move investor sentiment. Much of the focus centered on Thursday's consumer price data, which eased jitters over the duration of the current inflation wave.</p>\n<p>\"It’s a muted day today,\" Oliver Pursche, senior vice president at Wealthspire Advisors, in New York. \"The summer is settling in, people are slipping out of work early and there’s nothing in the news that’s going to materially drive the market in either direction.\"</p>\n<p>\"So, investors are going to wait until earnings season.\"</p>\n<p>The Federal Reserve has repeatedly said that near-term price surges will not metastasize into lasting inflation, an assertion reflected in the University of Michigan's Consumer Sentiment report released on Friday, which showed inflation expectations easing from last month's spike.</p>\n<p>Investors now turn their attention to the Fed's statement at the conclusion of next week's two-day monetary policy meeting, which will be parsed for clues regarding the central bank's timetable for raising key interest rates.</p>\n<p>\"Our view continues to be that inflationary data is transient and we will be around the 2% mark for the year,\" Pursche added.</p>\n<p>Benchmark U.S. Treasury yields posted their biggest weekly drop in nearly a year, weighing on the interest-sensitive financial sector in recent sessions.</p>\n<p>The Food and Drug Administration is facing mounting criticism over its \"accelerated approval\" of Biogen Inc's</p>\n<p>Alzheimer's drug Aduhelm without strong evidence of its ability to combat the disease.</p>\n<p>Biogen shares, along with the broader healthcare sector&nbsp;ended the session lower.</p>\n<p>Unofficially, the Dow Jones Industrial Average rose 14.41 points, or 0.04%, to 34,480.65, the S&amp;P 500 gained 8.29 points, or 0.20%, to 4,247.47 and the Nasdaq Composite&nbsp;added 49.09 points, or 0.35%, to 14,069.42.</p>\n<p>Among the 11 major sectors in the S&amp;P 500, healthcare suffered the biggest percentage drop.</p>\n<p>Much of the trading volume this week was attributable to the ongoing social media-driven \"meme stock\" phenomenon, in which retail investors swarm around heavily shorted stocks.</p>\n<p>But meme stock moves were more muted on Friday, with AMC Entertainment outperforming.</p>\n<p>(Reporting by Stephen Culp in New York Additional reporting by Ambar Warrick and Devik Jain in Bengaluru Editing by Matthew Lewis and Cynthia Osterman)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SH":"标普500反向ETF","IVV":"标普500指数ETF","SSO":"两倍做多标普500ETF","OEF":"标普100指数ETF-iShares","SPXU":"三倍做空标普500ETF","TQQQ":"纳指三倍做多ETF","SQQQ":"纳指三倍做空ETF","DXD":"道指两倍做空ETF","QLD":"纳指两倍做多ETF",".DJI":"道琼斯","PSQ":"纳指反向ETF",".IXIC":"NASDAQ Composite","DDM":"道指两倍做多ETF","SDOW":"道指三倍做空ETF-ProShares","OEX":"标普100",".SPX":"S&P 500 Index","SDS":"两倍做空标普500ETF","QQQ":"纳指100ETF","DOG":"道指反向ETF","DJX":"1/100道琼斯","UDOW":"道指三倍做多ETF-ProShares","UPRO":"三倍做多标普500ETF","QID":"纳指两倍做空ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142204074","content_text":"NEW YORK, June 11 (Reuters) - The S&P 500 closed nominally higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.\nEconomically sensitive smallcaps and transports notched solid gains, outperforming the broader market.\nFor the week, the S&P and the Nasdaq advanced from last Friday's close, while the Dow posted a weekly loss.\nBut the indexes have been range-bound, with few catalysts to move investor sentiment. Much of the focus centered on Thursday's consumer price data, which eased jitters over the duration of the current inflation wave.\n\"It’s a muted day today,\" Oliver Pursche, senior vice president at Wealthspire Advisors, in New York. \"The summer is settling in, people are slipping out of work early and there’s nothing in the news that’s going to materially drive the market in either direction.\"\n\"So, investors are going to wait until earnings season.\"\nThe Federal Reserve has repeatedly said that near-term price surges will not metastasize into lasting inflation, an assertion reflected in the University of Michigan's Consumer Sentiment report released on Friday, which showed inflation expectations easing from last month's spike.\nInvestors now turn their attention to the Fed's statement at the conclusion of next week's two-day monetary policy meeting, which will be parsed for clues regarding the central bank's timetable for raising key interest rates.\n\"Our view continues to be that inflationary data is transient and we will be around the 2% mark for the year,\" Pursche added.\nBenchmark U.S. Treasury yields posted their biggest weekly drop in nearly a year, weighing on the interest-sensitive financial sector in recent sessions.\nThe Food and Drug Administration is facing mounting criticism over its \"accelerated approval\" of Biogen Inc's\nAlzheimer's drug Aduhelm without strong evidence of its ability to combat the disease.\nBiogen shares, along with the broader healthcare sector ended the session lower.\nUnofficially, the Dow Jones Industrial Average rose 14.41 points, or 0.04%, to 34,480.65, the S&P 500 gained 8.29 points, or 0.20%, to 4,247.47 and the Nasdaq Composite added 49.09 points, or 0.35%, to 14,069.42.\nAmong the 11 major sectors in the S&P 500, healthcare suffered the biggest percentage drop.\nMuch of the trading volume this week was attributable to the ongoing social media-driven \"meme stock\" phenomenon, in which retail investors swarm around heavily shorted stocks.\nBut meme stock moves were more muted on Friday, with AMC Entertainment outperforming.\n(Reporting by Stephen Culp in New York Additional reporting by Ambar Warrick and Devik Jain in Bengaluru Editing by Matthew Lewis and Cynthia Osterman)","news_type":1},"isVote":1,"tweetType":1,"viewCount":539,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3565591020581408","authorId":"3565591020581408","name":"COYGrrr","avatar":"https://static.tigerbbs.com/bf6dc0e39d6a47cc606e845745162119","crmLevel":2,"crmLevelSwitch":1,"idStr":"3565591020581408","authorIdStr":"3565591020581408"},"content":"Please comment baCk pls","text":"Please comment baCk pls","html":"Please comment baCk pls"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114540426,"gmtCreate":1623081913165,"gmtModify":1704195773572,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"Pls comment and like","listText":"Pls comment and like","text":"Pls comment and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/114540426","repostId":"1196162025","repostType":4,"repost":{"id":"1196162025","pubTimestamp":1623049574,"share":"https://ttm.financial/m/news/1196162025?lang=&edition=fundamental","pubTime":"2021-06-07 15:06","market":"us","language":"en","title":"The second-half recovery is underway, and these are the top stocks to own, analysts say","url":"https://stock-news.laohu8.com/highlight/detail?id=1196162025","media":"cnbc","summary":"The reopening is well underway, and this week Wall Street analysts named some of their top ideas as ","content":"<div>\n<p>The reopening is well underway, and this week Wall Street analysts named some of their top ideas as the second half of 2021 nears.Analysts say the time is now for investors to begin taking advantage ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/06/analysts-like-top-stocks-for-the-recovery-match-booking-holdings.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The second-half recovery is underway, and these are the top stocks to own, analysts say</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe second-half recovery is underway, and these are the top stocks to own, analysts say\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 15:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/06/analysts-like-top-stocks-for-the-recovery-match-booking-holdings.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The reopening is well underway, and this week Wall Street analysts named some of their top ideas as the second half of 2021 nears.Analysts say the time is now for investors to begin taking advantage ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/06/analysts-like-top-stocks-for-the-recovery-match-booking-holdings.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BKNG":"Booking Holdings","MTCH":"Match Group, Inc.","SPG":"西蒙地产","AUD":"Audacy Inc.","WMG":"华纳音乐"},"source_url":"https://www.cnbc.com/2021/06/06/analysts-like-top-stocks-for-the-recovery-match-booking-holdings.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1196162025","content_text":"The reopening is well underway, and this week Wall Street analysts named some of their top ideas as the second half of 2021 nears.Analysts say the time is now for investors to begin taking advantage of the economic recovery and the growing number of quality buying opportunities.CNBC Pro combed through the top Wall Street research to find stocks that should bounce back quickly as 2021 rolls on.They include:Audacy,Booking Holdings,Warner Music Group,MatchandSimon.Match GroupThe online dating app company is poised to break out as mobility improves, according to Susquehanna analyst Shyam Patil.“Lots of upside potential still left ahead,” Patil wrote in a recent note.Match, which owns Tinder and several other dating websites, reported a robust earnings report in early may where it beat on revenue.“Tinder is continuing its momentum, and non-Tinder brands are crushing expectations, reaching a new record of 30% y/y growth in 1Q,” he said.Even as shares are down about 8.7% this year and have struggled under the weight of the pandemic, Patil said investors should stick with the stock.“We see MTCH as one of the strongest business franchises in the Internet sector, believe a likely second-half recovery should be a strong tail wind and would recommend taking advantage of the recent dip in the shares,” he wrote.It should be no surprise then, Patil added, that Match revenue continues to accelerate, especially as consumers reenter society.“MTCH noted that momentum is continuing across the portfolio, partially driven by the vaccine rollouts, particularly in the U.S.,” the firm wrote.Simon Property GroupA strong recovery is finally in sight for the beleaguered real estate investment trust and owner of malls and outlet centers, Piper Sandler analyst Alexander Goldfarb wrote in a recent note.The firm raised its price target on Simon to a Street high price target of $150 per share from $130 after the company reported strong first-quarter earnings in May.“All in all, the strong 1Q21 beat and guidance increase, from a team known to be conservative, bodes well for the balance of this year into next,” he said.Additionally, March sales were back to 2019 levels and that should give investors confidence that more foot traffic is just around corner, Goldfarb said.“As the return to normalcy accelerates, we expect the retail landscape to continue its robust rebound, especially into a mask-free 2021 holiday season,” he said.Goldfarb also predicted that consumers may see a familiar face return to Simon malls as it gets closer to December.“This even opens the door for a return of Santa in-person for the holidays, which further showcases the importance of the mall within the consumer landscape,” Goldfarb said.Shares of Simon are up about 55% this year.AudacyInvestors should buy the dip in shares of the broadcast and website radio platform company, Wells Fargo analyst Steven Cahall said in a note to clients.The company, formerly known as Radio.com, is coming off a mixed first-quarter earnings report, but Cahall said he believes local customer spending is finally picking up and in some cases exceeding 2019 levels.“Audacy remains in our 2H recovery bucket as we expect the local ad market will snap back with reopening,” he wrote.A return to growth in the second quarter is also possible, making the stock attractive right now, Cahall said.“There are early signs of pent-up demand in impacted verticals, such as restaurants, retail, and sporting events — and we believe the combination of small- and mid-sized businesses returning, local events coming back and digital revenue growth will drive a strong top line acceleration in 2H21,” he said.The stock is also cheap, according to Cahall, who has Street high price target of $7 per share on Audacy.“We see no reason why reopening won’t happen so the recent pullback presents a nice entry point for this value stock, in our view,” the firm wrote.Shares finished the week down 1.8%.Warner Music Group - Guggenheim, Buy rating“WMG delivered strong F2Q results with double-digit revenue growth at both Recorded Music and Music Publishing. Importantly, the company’s investments in international growth and digital initiatives support our positive long-term view based on unique intellectual property control, leadership position in new content sourcing and increasing exposure to secular growth businesses. Looking forward, we expect continued revenue strength in streaming/digital driven by a strong 2H release slate & expanded partnerships as well as recovery of COVID impacted businesses like live performances.Match - Susquehanna, Positive rating“Upside Potential Still Left Ahead. … We see MTCH as one of the strongest business franchises in the Internet sector, believe a likely 2H recovery should be a strong tailwind, and would recommend taking advantage of the recent dip in the shares. Tinder is continuing its momentum, and non-Tinder brands are crushing expectations, reaching a new record of 30% y/y growth in 1Q. We view the outlook as solid yet conservative and believe MTCH has an opportunity to further accelerate revenue in 2Q. … MTCH noted that momentum is continuing across the portfolio, partially driven by the vaccine rollouts, particularly in the U.S.”Simon Property - Piper Sandler, Overweight rating“As the return to normalcy accelerates, we expect the retail landscape to continue its robust rebound, especially into a mask-free 2021 holiday season. … Notably, sales in March were back up to 2019 levels, and with the change in CDC guidance we expect an increasing number of shoppers will feel comfortable shopping indoors post-vaccine. This even opens the door for a return of Santa in-person for the holidays, which further showcases the importance of the mall within the consumer landscape. … The strong 1Q21 beat and guidance increase, from a team known to be conservative, bodes well for the balance of this year into next.”Audacy - Wells Fargo, Overweight rating“While the local ad recovery has lagged national to begin the year, AUD expects a hockey stick return to growth beginning in 2Q. … We see no reason why reopening won’t happen so the recent pullback presents a nice entry point for this value stock, in our view. … There are early signs of pent-up demand in impacted verticals, such as restaurants, retail, and sporting events — and we believe the combination of SMB’s returning, local events coming back and digital revenue growth will drive a strong top line acceleration in 2H21. … AUD remains in our 2H recovery bucket as we expect the local ad market will snap back with reopening.”Booking Holdings - Wolfe, Outperform rating“BKNG reported mixed 1Q results, as total bookings beat consensus estimates by 19%, while Revenue and EBITDA were 2% and $90m below the Street, respectively. Management discussed improving trends through April, with U.S. hotel room nights above pre-COVID levels, as pent-up consumer demand is expected to drive a strong summer travel rebound. Trends across Europe remain more challenged given lagging vaccination rates but are expected to improve ahead of the summer months. Overall, near term results remain at depressed levels, but demand trends are picking up and hopes of a strong 2H recovery are intact.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":614,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":192214112,"gmtCreate":1621211176436,"gmtModify":1704353902258,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"Like pls.","listText":"Like pls.","text":"Like pls.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/192214112","repostId":"1195301764","repostType":4,"isVote":1,"tweetType":1,"viewCount":171,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":157275154,"gmtCreate":1625585773478,"gmtModify":1703744504571,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/157275154","repostId":"1142221624","repostType":4,"repost":{"id":"1142221624","pubTimestamp":1625585310,"share":"https://ttm.financial/m/news/1142221624?lang=&edition=fundamental","pubTime":"2021-07-06 23:28","market":"us","language":"en","title":"MRIN Stock: Why Reddit Investors Are Sending Marin Software Higher Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1142221624","media":"investorplace","summary":"Marin Software(NASDAQ:MRIN) stock is soaring higher on Tuesday as Reddit traders continue to pump up","content":"<p><b>Marin Software</b>(NASDAQ:<b><u>MRIN</u></b>) stock is soaring higher on Tuesday as Reddit traders continue to pump up the company’s shares.</p>\n<p>So why exactly are Reddit investors taking such a liking to MRIN stock today? There’s no recent news that would result in increasing interest from investors. That includes from inside or outside the company.</p>\n<p>Even if we head over to Reddit, it doesn’t look like those traders know why shares of MRIN stock are on the move today. Here’s a few examples of what users are saying.</p>\n<blockquote>\n <ul>\n  <li>“How the hell do i get in on meme stocks BEFORE they rocket?! Lol #MRIN” —thejet6969</li>\n  <li>“When y’all gon hop on MRIN?? That shit been flying under the radar with crazy volume and well over 100% short interest.” —chizbejoe</li>\n  <li>“Full on FOMO let’s go MRIN! Idk why, I’ll do my DD later. I like green crayons.” —amandarawrr</li>\n  <li>“Is there any solid reason why MRIN &amp; BLIN are flying or are they meme stocks now lol.” —friedchicken4health</li>\n </ul>\n</blockquote>\n<p>Even without any solid news sending MRIN stock higher today, there’s heavy trading of shares that investors should be aware of. As of this writing, more than 25 million shares of the stock have changed hands. That’s a major jump in morning volatility compared to the company’s daily average trading volume of about 20.6 million shares.</p>\n<p>MRIN stock was up 18.5% as of Tuesday morning and is up 1,109.6% since the start of the year.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MRIN Stock: Why Reddit Investors Are Sending Marin Software Higher Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMRIN Stock: Why Reddit Investors Are Sending Marin Software Higher Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 23:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/07/mrin-stock-why-reddit-investors-are-sending-marin-software-higher-today/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Marin Software(NASDAQ:MRIN) stock is soaring higher on Tuesday as Reddit traders continue to pump up the company’s shares.\nSo why exactly are Reddit investors taking such a liking to MRIN stock today?...</p>\n\n<a href=\"https://investorplace.com/2021/07/mrin-stock-why-reddit-investors-are-sending-marin-software-higher-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRIN":"Marin Software Inc."},"source_url":"https://investorplace.com/2021/07/mrin-stock-why-reddit-investors-are-sending-marin-software-higher-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142221624","content_text":"Marin Software(NASDAQ:MRIN) stock is soaring higher on Tuesday as Reddit traders continue to pump up the company’s shares.\nSo why exactly are Reddit investors taking such a liking to MRIN stock today? There’s no recent news that would result in increasing interest from investors. That includes from inside or outside the company.\nEven if we head over to Reddit, it doesn’t look like those traders know why shares of MRIN stock are on the move today. Here’s a few examples of what users are saying.\n\n\n“How the hell do i get in on meme stocks BEFORE they rocket?! Lol #MRIN” —thejet6969\n“When y’all gon hop on MRIN?? That shit been flying under the radar with crazy volume and well over 100% short interest.” —chizbejoe\n“Full on FOMO let’s go MRIN! Idk why, I’ll do my DD later. I like green crayons.” —amandarawrr\n“Is there any solid reason why MRIN & BLIN are flying or are they meme stocks now lol.” —friedchicken4health\n\n\nEven without any solid news sending MRIN stock higher today, there’s heavy trading of shares that investors should be aware of. As of this writing, more than 25 million shares of the stock have changed hands. That’s a major jump in morning volatility compared to the company’s daily average trading volume of about 20.6 million shares.\nMRIN stock was up 18.5% as of Tuesday morning and is up 1,109.6% since the start of the year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":421,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098166985,"gmtCreate":1644047779575,"gmtModify":1676533886158,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"Like pla","listText":"Like pla","text":"Like pla","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098166985","repostId":"1130580421","repostType":4,"repost":{"id":"1130580421","pubTimestamp":1644040812,"share":"https://ttm.financial/m/news/1130580421?lang=&edition=fundamental","pubTime":"2022-02-05 14:00","market":"us","language":"en","title":"2022 Could be a Success or a Lost Opportunity for Novavax","url":"https://stock-news.laohu8.com/highlight/detail?id=1130580421","media":"InvestorPlace","summary":"Novavax can either generate a boost of sales or lose an opportunity in the industry of vaccines against coronavirus","content":"<html><head></head><body><p><b>Novavax, Inc</b>. (NASDAQ:<b><u>NVAX</u></b><u>)</u> has had a tough year with losses of approximately 68%. It has already declined about 37% year-to-date, as well. However, as of Feb. 3, 2022, the stock has a 5-day return of nearly 25%. This increased volatility in the stock price is primarily news-driven.</p><p>Novavax is trying to become active in the global industry of vaccines against the coronavirus to put an end to the pandemic so all of us can return to normal conditions at which social distancing will be a distant memory, along with wearing face masks.</p><p><b>Novavax Business News</b></p><p>The latest business news is that Novavax got conditional authorization in the U.K for its protein-based Covid-19 vaccine called Nuvaxovid. It is reported that “the U.K. has already ordered up to 60 million doses of Novavax’s vaccine.”</p><p>The company announced that it filed for authorization in the U.S. market in late Jan. 2022. Novavax has been granted provisional registration for its vaccine in Australia. Additionally, in South Korea, the Ministry of Food and Drug Safety has approved the firm’s vaccine. At the same time the “European Commission (EC) has granted Novavax conditional marketing authorization (CMA) for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.”</p><p>Novavax also submitted for emergency use authorization of its vaccine in South Africa.</p><p>A lot of this news is a catalyst for NVAX stock. The greatest impact on the stock probably would be U.S. market approval for Nuvaxovid. Investors waiting for further positive news are already building a bull case for Novavax.</p><p><b>Bullish Scenario for NVAX Stock</b></p><p>Novavax’s vaccine is the fifth vaccine approved by the E.U. Protein vaccines like Nuvaxovid can do a lot for the global vaccination campaign. This is because they work differently from the vaccines currently available in the E.U., which are based on either mRNA technology, such as Pfizer and Moderna, or viral vector technology, such as AstraZeneca and Johnson &amp; Johnson.</p><p>If unvaccinated people are not biased against vaccination to protect from Covid-19, they could soon be vaccinated with protein vaccines such as Nuvaxovid. Such protein vaccines have been used for decades to protect against polio, tetanus, hepatitis B, and the flu. They also offer very good protection against coronavirus and cause even fewer side effects than vaccines that are already approved.</p><p>Also, these vaccines are important. Richer countries are so preoccupied with booster vaccinations and closing vaccination gaps that they may forget that in poor countries very few people have been vaccinated.</p><p>Protein-based vaccines could also make a significant contribution to the market. They are relatively inexpensive to produce and can be transported and stored at 2° to 8° C much more easily than mRNA vaccines, which need to be frozen.</p><p>Novavax will first supply its vaccine in poorer countries like Africa. The Novavax vaccine is a combination vaccine that is said to protect against the coronavirus and the flu at the same time. According to Novavax, initially,100 million doses of the vaccine could be produced per month. They later expect to be able to produce 150 million doses of the vaccine per month.</p><p>Europe being supplied with Nuvaxovid is certainly big news for Novavax. The U.S. Food and Drug Administration (FDA) may become biased and send the green light for the biotechnology company to boost its sales, especially if its price is cheaper than other vaccines.</p><p><b>Bearish Case for NVAX Stock</b></p><p>Third quarter (Q3) 2021 financial results showed a year-over-year increase of 14% for revenue to $179 million and a 38% increase of total expenses to $486 million. Loss from operations widened to $307 million compared to a loss of $194 million in Q3 2020. Net loss also widened to $322 million compared to a net loss of $197 million in Q3 2020.</p><p>The firm has poor financial strength as the debt-to-equity (D/E) ratio of 0.70 is considered high for a money-losing business that has been burning cash over the past five consecutive years.</p><p>Another negative sign for NVAX stock is that shareholders have been substantially diluted in the past year, with total shares outstanding growing by 137.4%.</p><p><b>Novavax: At an Inflection Point Now</b></p><p>The company has positive news that sparks enthusiasm. The broader fundamental analysis, however, is not supportive of the company. Widening losses and burning cash must be addressed fast and radically for a stock price rebound to occur and last.</p><p>I remain bearish on NVAX stock, waiting for sales updates as the key catalyst.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Could be a Success or a Lost Opportunity for Novavax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Could be a Success or a Lost Opportunity for Novavax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 14:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/02/2022-could-be-a-success-or-a-lost-opportunity-for-novavax/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax, Inc. (NASDAQ:NVAX) has had a tough year with losses of approximately 68%. It has already declined about 37% year-to-date, as well. However, as of Feb. 3, 2022, the stock has a 5-day return of...</p>\n\n<a href=\"https://investorplace.com/2022/02/2022-could-be-a-success-or-a-lost-opportunity-for-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/02/2022-could-be-a-success-or-a-lost-opportunity-for-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130580421","content_text":"Novavax, Inc. (NASDAQ:NVAX) has had a tough year with losses of approximately 68%. It has already declined about 37% year-to-date, as well. However, as of Feb. 3, 2022, the stock has a 5-day return of nearly 25%. This increased volatility in the stock price is primarily news-driven.Novavax is trying to become active in the global industry of vaccines against the coronavirus to put an end to the pandemic so all of us can return to normal conditions at which social distancing will be a distant memory, along with wearing face masks.Novavax Business NewsThe latest business news is that Novavax got conditional authorization in the U.K for its protein-based Covid-19 vaccine called Nuvaxovid. It is reported that “the U.K. has already ordered up to 60 million doses of Novavax’s vaccine.”The company announced that it filed for authorization in the U.S. market in late Jan. 2022. Novavax has been granted provisional registration for its vaccine in Australia. Additionally, in South Korea, the Ministry of Food and Drug Safety has approved the firm’s vaccine. At the same time the “European Commission (EC) has granted Novavax conditional marketing authorization (CMA) for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.”Novavax also submitted for emergency use authorization of its vaccine in South Africa.A lot of this news is a catalyst for NVAX stock. The greatest impact on the stock probably would be U.S. market approval for Nuvaxovid. Investors waiting for further positive news are already building a bull case for Novavax.Bullish Scenario for NVAX StockNovavax’s vaccine is the fifth vaccine approved by the E.U. Protein vaccines like Nuvaxovid can do a lot for the global vaccination campaign. This is because they work differently from the vaccines currently available in the E.U., which are based on either mRNA technology, such as Pfizer and Moderna, or viral vector technology, such as AstraZeneca and Johnson & Johnson.If unvaccinated people are not biased against vaccination to protect from Covid-19, they could soon be vaccinated with protein vaccines such as Nuvaxovid. Such protein vaccines have been used for decades to protect against polio, tetanus, hepatitis B, and the flu. They also offer very good protection against coronavirus and cause even fewer side effects than vaccines that are already approved.Also, these vaccines are important. Richer countries are so preoccupied with booster vaccinations and closing vaccination gaps that they may forget that in poor countries very few people have been vaccinated.Protein-based vaccines could also make a significant contribution to the market. They are relatively inexpensive to produce and can be transported and stored at 2° to 8° C much more easily than mRNA vaccines, which need to be frozen.Novavax will first supply its vaccine in poorer countries like Africa. The Novavax vaccine is a combination vaccine that is said to protect against the coronavirus and the flu at the same time. According to Novavax, initially,100 million doses of the vaccine could be produced per month. They later expect to be able to produce 150 million doses of the vaccine per month.Europe being supplied with Nuvaxovid is certainly big news for Novavax. The U.S. Food and Drug Administration (FDA) may become biased and send the green light for the biotechnology company to boost its sales, especially if its price is cheaper than other vaccines.Bearish Case for NVAX StockThird quarter (Q3) 2021 financial results showed a year-over-year increase of 14% for revenue to $179 million and a 38% increase of total expenses to $486 million. Loss from operations widened to $307 million compared to a loss of $194 million in Q3 2020. Net loss also widened to $322 million compared to a net loss of $197 million in Q3 2020.The firm has poor financial strength as the debt-to-equity (D/E) ratio of 0.70 is considered high for a money-losing business that has been burning cash over the past five consecutive years.Another negative sign for NVAX stock is that shareholders have been substantially diluted in the past year, with total shares outstanding growing by 137.4%.Novavax: At an Inflection Point NowThe company has positive news that sparks enthusiasm. The broader fundamental analysis, however, is not supportive of the company. Widening losses and burning cash must be addressed fast and radically for a stock price rebound to occur and last.I remain bearish on NVAX stock, waiting for sales updates as the key catalyst.","news_type":1},"isVote":1,"tweetType":1,"viewCount":378,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182232851,"gmtCreate":1623576180373,"gmtModify":1704206510910,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"Like and comment&nbsp;","listText":"Like and comment&nbsp;","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/182232851","repostId":"2142204074","repostType":4,"repost":{"id":"2142204074","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623441637,"share":"https://ttm.financial/m/news/2142204074?lang=&edition=fundamental","pubTime":"2021-06-12 04:00","market":"us","language":"en","title":"S&P ekes out gains to close languid week","url":"https://stock-news.laohu8.com/highlight/detail?id=2142204074","media":"Reuters","summary":"NEW YORK, June 11  - The S&P 500 closed nominally higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.Economically sensitive smallcaps and transports notched solid gains, outperforming the broader market.For the week, the S&P and the Nasdaq advanced from last Friday's close, while the Dow posted a weekly loss.But th","content":"<p>NEW YORK, June 11 (Reuters) - The S&amp;P 500 closed nominally higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.</p>\n<p>Economically sensitive smallcaps and transports&nbsp;notched solid gains, outperforming the broader market.</p>\n<p>For the week, the S&amp;P and the Nasdaq advanced from last Friday's close, while the Dow posted a weekly loss.</p>\n<p>But the indexes have been range-bound, with few catalysts to move investor sentiment. Much of the focus centered on Thursday's consumer price data, which eased jitters over the duration of the current inflation wave.</p>\n<p>\"It’s a muted day today,\" Oliver Pursche, senior vice president at Wealthspire Advisors, in New York. \"The summer is settling in, people are slipping out of work early and there’s nothing in the news that’s going to materially drive the market in either direction.\"</p>\n<p>\"So, investors are going to wait until earnings season.\"</p>\n<p>The Federal Reserve has repeatedly said that near-term price surges will not metastasize into lasting inflation, an assertion reflected in the University of Michigan's Consumer Sentiment report released on Friday, which showed inflation expectations easing from last month's spike.</p>\n<p>Investors now turn their attention to the Fed's statement at the conclusion of next week's two-day monetary policy meeting, which will be parsed for clues regarding the central bank's timetable for raising key interest rates.</p>\n<p>\"Our view continues to be that inflationary data is transient and we will be around the 2% mark for the year,\" Pursche added.</p>\n<p>Benchmark U.S. Treasury yields posted their biggest weekly drop in nearly a year, weighing on the interest-sensitive financial sector in recent sessions.</p>\n<p>The Food and Drug Administration is facing mounting criticism over its \"accelerated approval\" of Biogen Inc's</p>\n<p>Alzheimer's drug Aduhelm without strong evidence of its ability to combat the disease.</p>\n<p>Biogen shares, along with the broader healthcare sector&nbsp;ended the session lower.</p>\n<p>Unofficially, the Dow Jones Industrial Average rose 14.41 points, or 0.04%, to 34,480.65, the S&amp;P 500 gained 8.29 points, or 0.20%, to 4,247.47 and the Nasdaq Composite&nbsp;added 49.09 points, or 0.35%, to 14,069.42.</p>\n<p>Among the 11 major sectors in the S&amp;P 500, healthcare suffered the biggest percentage drop.</p>\n<p>Much of the trading volume this week was attributable to the ongoing social media-driven \"meme stock\" phenomenon, in which retail investors swarm around heavily shorted stocks.</p>\n<p>But meme stock moves were more muted on Friday, with AMC Entertainment outperforming.</p>\n<p>(Reporting by Stephen Culp in New York Additional reporting by Ambar Warrick and Devik Jain in Bengaluru Editing by Matthew Lewis and Cynthia Osterman)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P ekes out gains to close languid week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P ekes out gains to close languid week\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-12 04:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, June 11 (Reuters) - The S&amp;P 500 closed nominally higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.</p>\n<p>Economically sensitive smallcaps and transports&nbsp;notched solid gains, outperforming the broader market.</p>\n<p>For the week, the S&amp;P and the Nasdaq advanced from last Friday's close, while the Dow posted a weekly loss.</p>\n<p>But the indexes have been range-bound, with few catalysts to move investor sentiment. Much of the focus centered on Thursday's consumer price data, which eased jitters over the duration of the current inflation wave.</p>\n<p>\"It’s a muted day today,\" Oliver Pursche, senior vice president at Wealthspire Advisors, in New York. \"The summer is settling in, people are slipping out of work early and there’s nothing in the news that’s going to materially drive the market in either direction.\"</p>\n<p>\"So, investors are going to wait until earnings season.\"</p>\n<p>The Federal Reserve has repeatedly said that near-term price surges will not metastasize into lasting inflation, an assertion reflected in the University of Michigan's Consumer Sentiment report released on Friday, which showed inflation expectations easing from last month's spike.</p>\n<p>Investors now turn their attention to the Fed's statement at the conclusion of next week's two-day monetary policy meeting, which will be parsed for clues regarding the central bank's timetable for raising key interest rates.</p>\n<p>\"Our view continues to be that inflationary data is transient and we will be around the 2% mark for the year,\" Pursche added.</p>\n<p>Benchmark U.S. Treasury yields posted their biggest weekly drop in nearly a year, weighing on the interest-sensitive financial sector in recent sessions.</p>\n<p>The Food and Drug Administration is facing mounting criticism over its \"accelerated approval\" of Biogen Inc's</p>\n<p>Alzheimer's drug Aduhelm without strong evidence of its ability to combat the disease.</p>\n<p>Biogen shares, along with the broader healthcare sector&nbsp;ended the session lower.</p>\n<p>Unofficially, the Dow Jones Industrial Average rose 14.41 points, or 0.04%, to 34,480.65, the S&amp;P 500 gained 8.29 points, or 0.20%, to 4,247.47 and the Nasdaq Composite&nbsp;added 49.09 points, or 0.35%, to 14,069.42.</p>\n<p>Among the 11 major sectors in the S&amp;P 500, healthcare suffered the biggest percentage drop.</p>\n<p>Much of the trading volume this week was attributable to the ongoing social media-driven \"meme stock\" phenomenon, in which retail investors swarm around heavily shorted stocks.</p>\n<p>But meme stock moves were more muted on Friday, with AMC Entertainment outperforming.</p>\n<p>(Reporting by Stephen Culp in New York Additional reporting by Ambar Warrick and Devik Jain in Bengaluru Editing by Matthew Lewis and Cynthia Osterman)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SH":"标普500反向ETF","IVV":"标普500指数ETF","SSO":"两倍做多标普500ETF","OEF":"标普100指数ETF-iShares","SPXU":"三倍做空标普500ETF","TQQQ":"纳指三倍做多ETF","SQQQ":"纳指三倍做空ETF","DXD":"道指两倍做空ETF","QLD":"纳指两倍做多ETF",".DJI":"道琼斯","PSQ":"纳指反向ETF",".IXIC":"NASDAQ Composite","DDM":"道指两倍做多ETF","SDOW":"道指三倍做空ETF-ProShares","OEX":"标普100",".SPX":"S&P 500 Index","SDS":"两倍做空标普500ETF","QQQ":"纳指100ETF","DOG":"道指反向ETF","DJX":"1/100道琼斯","UDOW":"道指三倍做多ETF-ProShares","UPRO":"三倍做多标普500ETF","QID":"纳指两倍做空ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142204074","content_text":"NEW YORK, June 11 (Reuters) - The S&P 500 closed nominally higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.\nEconomically sensitive smallcaps and transports notched solid gains, outperforming the broader market.\nFor the week, the S&P and the Nasdaq advanced from last Friday's close, while the Dow posted a weekly loss.\nBut the indexes have been range-bound, with few catalysts to move investor sentiment. Much of the focus centered on Thursday's consumer price data, which eased jitters over the duration of the current inflation wave.\n\"It’s a muted day today,\" Oliver Pursche, senior vice president at Wealthspire Advisors, in New York. \"The summer is settling in, people are slipping out of work early and there’s nothing in the news that’s going to materially drive the market in either direction.\"\n\"So, investors are going to wait until earnings season.\"\nThe Federal Reserve has repeatedly said that near-term price surges will not metastasize into lasting inflation, an assertion reflected in the University of Michigan's Consumer Sentiment report released on Friday, which showed inflation expectations easing from last month's spike.\nInvestors now turn their attention to the Fed's statement at the conclusion of next week's two-day monetary policy meeting, which will be parsed for clues regarding the central bank's timetable for raising key interest rates.\n\"Our view continues to be that inflationary data is transient and we will be around the 2% mark for the year,\" Pursche added.\nBenchmark U.S. Treasury yields posted their biggest weekly drop in nearly a year, weighing on the interest-sensitive financial sector in recent sessions.\nThe Food and Drug Administration is facing mounting criticism over its \"accelerated approval\" of Biogen Inc's\nAlzheimer's drug Aduhelm without strong evidence of its ability to combat the disease.\nBiogen shares, along with the broader healthcare sector ended the session lower.\nUnofficially, the Dow Jones Industrial Average rose 14.41 points, or 0.04%, to 34,480.65, the S&P 500 gained 8.29 points, or 0.20%, to 4,247.47 and the Nasdaq Composite added 49.09 points, or 0.35%, to 14,069.42.\nAmong the 11 major sectors in the S&P 500, healthcare suffered the biggest percentage drop.\nMuch of the trading volume this week was attributable to the ongoing social media-driven \"meme stock\" phenomenon, in which retail investors swarm around heavily shorted stocks.\nBut meme stock moves were more muted on Friday, with AMC Entertainment outperforming.\n(Reporting by Stephen Culp in New York Additional reporting by Ambar Warrick and Devik Jain in Bengaluru Editing by Matthew Lewis and Cynthia Osterman)","news_type":1},"isVote":1,"tweetType":1,"viewCount":539,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3565591020581408","authorId":"3565591020581408","name":"COYGrrr","avatar":"https://static.tigerbbs.com/bf6dc0e39d6a47cc606e845745162119","crmLevel":2,"crmLevelSwitch":1,"idStr":"3565591020581408","authorIdStr":"3565591020581408"},"content":"Please comment baCk pls","text":"Please comment baCk pls","html":"Please comment baCk pls"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161748113,"gmtCreate":1623941812032,"gmtModify":1703824202103,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"Like pla","listText":"Like pla","text":"Like pla","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/161748113","repostId":"1179547045","repostType":4,"repost":{"id":"1179547045","pubTimestamp":1623941450,"share":"https://ttm.financial/m/news/1179547045?lang=&edition=fundamental","pubTime":"2021-06-17 22:50","market":"us","language":"en","title":"Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1179547045","media":"thestreet","summary":"Shares of Clearside Biomedical(CLSD)  jumped on Thursday after analysts at Wedbush tripled their pri","content":"<p>Shares of Clearside Biomedical(<b>CLSD</b>) &nbsp;jumped on Thursday after analysts at Wedbush tripled their price target for the company following positive data from the early stage eye treatment study.</p>\n<p>Wedbush analyst Liana Moussatos rates the stock outperform and tripled her price target to $18 a share.</p>\n<p>\"We find these initial results encouraging by first establishing a clear foundation of safety,\" Moussatos said.</p>\n<p>Shares of Clearside Biomedical at last check jumped 36% to $5.53. The shares on Thursday have traded at a 52-week high $5.66, up 39%. And they've bounced off a 52-week low $1.25, touched at the end of October.</p>\n<p>Clearside shares have been volatile, falling as low as $2.24 per share in late March. But since the calendar flipped to June, the stock as jumped more than 50%, including Thursday's jump.</p>\n<p>Earlier this week the company&nbsp;reported progress in a clinical trial of CLS-AX, a drug for pretreated wet age-related macular degeneration.</p>\n<p>Clearside said the initial lowest planned dose of 0.03 mg CLS-AX was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed throughout the study.</p>\n<p>The company said the improvements were reflected in the BCVA score, or best corrected visual acuity, with five of six patients each gaining four or more letters.</p>\n<p>Earlier this week the results prompted an analyst to call the treatment \"a game changer.\" Roth Capital analyst Zegbeh Jallah reiterated a buy rating and $9 price target on Clearside after the company reported data from the study.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/clearside-biomedical-stock-jumps-on-wedbush-upgrade><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Clearside Biomedical(CLSD)  jumped on Thursday after analysts at Wedbush tripled their price target for the company following positive data from the early stage eye treatment study.\nWedbush ...</p>\n\n<a href=\"https://www.thestreet.com/investing/clearside-biomedical-stock-jumps-on-wedbush-upgrade\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLSD":"Clearside Biomedical Inc."},"source_url":"https://www.thestreet.com/investing/clearside-biomedical-stock-jumps-on-wedbush-upgrade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1179547045","content_text":"Shares of Clearside Biomedical(CLSD)  jumped on Thursday after analysts at Wedbush tripled their price target for the company following positive data from the early stage eye treatment study.\nWedbush analyst Liana Moussatos rates the stock outperform and tripled her price target to $18 a share.\n\"We find these initial results encouraging by first establishing a clear foundation of safety,\" Moussatos said.\nShares of Clearside Biomedical at last check jumped 36% to $5.53. The shares on Thursday have traded at a 52-week high $5.66, up 39%. And they've bounced off a 52-week low $1.25, touched at the end of October.\nClearside shares have been volatile, falling as low as $2.24 per share in late March. But since the calendar flipped to June, the stock as jumped more than 50%, including Thursday's jump.\nEarlier this week the company reported progress in a clinical trial of CLS-AX, a drug for pretreated wet age-related macular degeneration.\nClearside said the initial lowest planned dose of 0.03 mg CLS-AX was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed throughout the study.\nThe company said the improvements were reflected in the BCVA score, or best corrected visual acuity, with five of six patients each gaining four or more letters.\nEarlier this week the results prompted an analyst to call the treatment \"a game changer.\" Roth Capital analyst Zegbeh Jallah reiterated a buy rating and $9 price target on Clearside after the company reported data from the study.","news_type":1},"isVote":1,"tweetType":1,"viewCount":356,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150356654,"gmtCreate":1624888195278,"gmtModify":1703847100780,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150356654","repostId":"1150095060","repostType":4,"repost":{"id":"1150095060","pubTimestamp":1624874134,"share":"https://ttm.financial/m/news/1150095060?lang=&edition=fundamental","pubTime":"2021-06-28 17:55","market":"us","language":"en","title":"US IPO Week Ahead: DiDi makes its billion-dollar debut in a 17 IPO week","url":"https://stock-news.laohu8.com/highlight/detail?id=1150095060","media":"Renaissance Capital","summary":"17 IPOs are slated to raise $9.1 billion in this week, led by long-awaited Chinese ride-hailing giant $DiDi Global Inc.$.DiDi plans to raise $3.9 billion at a $67.5 billion market cap. DiDi is China’s dominant ride-hailing app, with 15 million drivers across 4,000 cities and towns. The unprofitable company saw revenue more than double in the 1Q21 as its business recovered post-pandemic.New and existing investors intend to purchase $1.3 billion of the IPO.Cybersecurity platform $SentinelOne, Inc$","content":"<p>17 IPOs are slated to raise $9.1 billion in this week, led by long-awaited Chinese ride-hailing giant<b>&nbsp;<a href=\"https://laohu8.com/S/DIDI\">DiDi Global Inc.</a>.</b></p>\n<p><b>DiDi</b>&nbsp;plans to raise $3.9 billion at a $67.5 billion market cap. DiDi is China’s dominant ride-hailing app, with 15 million drivers across 4,000 cities and towns. The unprofitable company saw revenue more than double in the 1Q21 as its business recovered post-pandemic.New and existing investors intend to purchase $1.3 billion of the IPO.</p>\n<p>Cybersecurity platform&nbsp;<b><a href=\"https://laohu8.com/S/S\">SentinelOne, Inc</a></b> plans to raise $880 million at an $8.2 billion market cap. SentinelOne's Singularity Platform is an AI-powered extended detection and response platform that ingests, correlates and queries petabytes of structured and unstructured data to provide autonomous cybersecurity defense. Fast growing and unprofitable, the company had over 4,700 customers as of 4/30/21, up from 2,700 a year prior.</p>\n<p>Turkish e-commerce platform&nbsp;<b>D-MARKET Electronic Services &amp; Trading</b>(HEPS) plans to raise $681 million at a $3.9 billion market cap. Operating under the name Hepsiburada, the company connected 33 million members, 9 million Active Customers, and a base of approximately 45 thousand Active Merchants in 2020. The company is fast growing but EBITDA swung negative in the 1Q21.</p>\n<p>Doughnut brand&nbsp;<a href=\"https://laohu8.com/S/DNUT\"><b>Krispy Kreme, Inc.</a> </b>plans to raise $600 million at a $3.8 billion market cap. Krispy Kreme is an omni-channel business operating through a network of doughnut shops, partnerships with retailers, and an e-Commerce and delivery business. The company has a long track record and strong brand awareness, though its growth strategy is unproven.</p>\n<p>Legal solutions provider&nbsp;<b><a href=\"https://laohu8.com/S/LZ\">LegalZoom.com, Inc</a> </b>plans to raise $488 million at a $5.3 billion market cap. LegalZoom states that it is a leading online platform for legal and compliance solutions, claiming that 10% of new LLCs and 5% of new corporations in the US were formed via LegalZoom in 2020. Profitable on an EBITDA basis in the 1Q21, the company operates across all 50 states and over 3,000 counties in the US.</p>\n<p>Identity verification platform&nbsp;<b><a href=\"https://laohu8.com/S/YOU\">Clear Secure, Inc.</a></b> plans to raise $376 million at a $4.1 billion market cap. Clear Secure's secure identity platform uses to automate the identity verification process, with main offerings including CLEAR Plus, a consumer aviation subscription service, and two mobile apps. As of 5/31/21, Clear Secure's network included 38 airports, 26 sports and entertainment partners, and 67 Health Pass-enabled partners.</p>\n<p>Chinese grocery delivery platform&nbsp;<b><a href=\"https://laohu8.com/S/DDL\">Dingdong (Cayman) Limited</a> </b>plans to raise $343 million at a $6.0 billion market cap. With fresh groceries as its core product categories, Dingdong states that it is the fastest growing on-demand e-commerce company in China. Unprofitable with explosive growth, the company had a 10% share of the on-demand e-commerce market by GMV in 2020.</p>\n<p>SaaS solutions provider&nbsp;<b><a href=\"https://laohu8.com/S/EVCM\">EverCommerce Inc.</a></b> plans to raise $325 million at a $3.4 billion market cap. EverCommerce is a leading provider of integrated, vertically-tailored SaaS solutions for service-based SMBs. The company serves over 500,000 customers across three core verticals: Home Services, Health Services, and Fitness &amp; Wellness Services.</p>\n<p>Software provider&nbsp;<b><a href=\"https://laohu8.com/S/INTA\">Intapp, Inc.</a> </b>plans to raise $278 million at a $1.9 billion market cap. Intapp provides industry-specific, cloud-based software solutions for the professional and financial services industry globally. The company had over 1,600 clients as of March 31, 2021, and it currently has more than 20 clients with contracts greater than $1 million of ARR.</p>\n<p>Online manufacturing marketplace&nbsp;<b><a href=\"https://laohu8.com/S/XMTR\">Xometry, Inc.</a></b> plans to raise $275 million at a $1.9 billion market cap. Xometry states that it is a leading AI-enabled marketplace for on-demand manufacturing. Its buyers include businesses ranging from self-funded start-ups to Fortune 100 companies. Since its inception, over 6.0 million parts have been manufactured through Xometry's platform.</p>\n<p><b><a href=\"https://laohu8.com/S/IAS\">Integral Ad Science Holding LLC</a> </b>plans to raise $240 million at a $2.5 billion market cap. The company’s technology provides metrics designed to verify that digital ads are served to a real person, viewable on-screen, and appear in a brand-safe and suitable environment in the correct geography. Profitable on an EBIT basis, Integral Ad Science served over 2,000 customers as of 3/31/21.</p>\n<p>Plus-sized women’s apparel brand&nbsp;<b><a href=\"https://laohu8.com/S/CURV\">Torrid Holdings</a> </b>plans to raise $156 million at a $2.1 billion market cap. Torrid is the largest direct-to-consumer brand of women's plus-size apparel and intimates in North America by net sales. The profitable company markets directly to consumers via physical stores and its e-commerce platform, which represented a majority of sales in the 12 months ended 5/1/21.</p>\n<p>Alzheimer’s biotech&nbsp;<b><a href=\"https://laohu8.com/S/ABOS\">Acumen Pharmaceuticals, Inc.</a></b> plans to raise $125 million at a $607 million market cap. The company's lead candidate, ACU193, is a humanized monoclonal antibody that selectively targets amyloid-beta oligomers. ACU193 entered a Phase 1 trial in patients with mild dementia or cognitive impairment due to AD in the 2Q21, with data expected by year end 2022.</p>\n<p>Digital financial services provider&nbsp;<b>AMTD Digital</b>(<a href=\"https://laohu8.com/S/HKD\">$(HKD)$</a>) plans to raise $120 million at a $1.4 billion market cap. AMTD Digital states that it is the \"fusion reactor\" at the core of the AMTD SpiderNet ecosystem, operating a comprehensive digital solutions platform in Asia. Profitable with explosive growth, the company primarily generates revenue from fees and commissions in two lines of business.</p>\n<p>Drug formulation developer&nbsp;<b>Aerovate Therapeutics</b>(<a href=\"https://laohu8.com/S/AVTE\">$(AVTE)$</a>) plans to raise $100 million at a $325 million market cap. Aerovate's initial focus is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH). The company has completed a Phase 1 study in healthy volunteers and expects to begin a Phase 2b/3 trial in PAH patients in the 2H21.</p>\n<p>Neuromodulation device provider<b>&nbsp;<a href=\"https://laohu8.com/S/CVRX\">CVRx Inc</a> </b>plans to raise $100 million at a $333 million market cap. CVRx manufactures and markets its minimally invasive neuromodulation solutions on its proprietary BAROSTIM platform. The company's states that its BAROSTEM NEO product is the first and only commercially available neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction.</p>\n<p>Belgium-listed&nbsp;<b>Nyxoah</b>(<a href=\"https://laohu8.com/S/NYXH\">$(NYXH)$</a>) plans to raise $87 million at an $803 million market cap. Nyxoah's lead product is the Genio system, a CE-marked, minimally-invasive hypoglossal neurostimulation therapy for obstructive sleep apnea. The company began generating revenue from Genio in Europe in July 2020 and is currently conducting a pivotal trial designed to support marketing authorization in the US.</p>\n<p><img src=\"https://static.tigerbbs.com/58f28d5f7f3b8e686c0bd006c2968b99\" tg-width=\"1131\" tg-height=\"684\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/508f1118f1d92b2b76391bc3610bd6c4\" tg-width=\"1131\" tg-height=\"657\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/ed04cd42fa30b460fcf67e07efa6ddc7\" tg-width=\"1130\" tg-height=\"166\" referrerpolicy=\"no-referrer\"></p>\n<p><b>IPO Market Snapshot</b></p>\n<p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 6/24/21, the Renaissance IPO Index was up 2.7% year-to-date, while the S&amp;P 500 was up 13.6%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Palantir Technologies (PLTR). The Renaissance International IPO Index was down 1.5% year-to-date, while the ACWX was up 10.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Smoore International and EQT Partners.</p>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: DiDi makes its billion-dollar debut in a 17 IPO week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: DiDi makes its billion-dollar debut in a 17 IPO week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-28 17:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/83318/US-IPO-Week-Ahead-DiDi-makes-its-billion-dollar-debut-in-a-17-IPO-week><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>17 IPOs are slated to raise $9.1 billion in this week, led by long-awaited Chinese ride-hailing giant DiDi Global Inc..\nDiDi plans to raise $3.9 billion at a $67.5 billion market cap. DiDi is China’s ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/83318/US-IPO-Week-Ahead-DiDi-makes-its-billion-dollar-debut-in-a-17-IPO-week\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABOS":"Acumen Pharmaceuticals, Inc.","HEPS":"D-MARKET Electronic Services & Trading","CVRX":"CVRx, Inc.","S":"SentinelOne, Inc","LZ":"LegalZoom.com, Inc","IAS":"Integral Ad Science Holding","INTA":"Intapp, Inc.","YOU":"Clear Secure, Inc.","XMTR":"Xometry, Inc.","EVCM":"EverCommerce Inc.","DNUT":"Krispy Kreme, Inc.","CURV":"Torrid Holdings","DIDI":"滴滴(已退市)","DDL":"叮咚买菜"},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/83318/US-IPO-Week-Ahead-DiDi-makes-its-billion-dollar-debut-in-a-17-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150095060","content_text":"17 IPOs are slated to raise $9.1 billion in this week, led by long-awaited Chinese ride-hailing giant DiDi Global Inc..\nDiDi plans to raise $3.9 billion at a $67.5 billion market cap. DiDi is China’s dominant ride-hailing app, with 15 million drivers across 4,000 cities and towns. The unprofitable company saw revenue more than double in the 1Q21 as its business recovered post-pandemic.New and existing investors intend to purchase $1.3 billion of the IPO.\nCybersecurity platform SentinelOne, Inc plans to raise $880 million at an $8.2 billion market cap. SentinelOne's Singularity Platform is an AI-powered extended detection and response platform that ingests, correlates and queries petabytes of structured and unstructured data to provide autonomous cybersecurity defense. Fast growing and unprofitable, the company had over 4,700 customers as of 4/30/21, up from 2,700 a year prior.\nTurkish e-commerce platform D-MARKET Electronic Services & Trading(HEPS) plans to raise $681 million at a $3.9 billion market cap. Operating under the name Hepsiburada, the company connected 33 million members, 9 million Active Customers, and a base of approximately 45 thousand Active Merchants in 2020. The company is fast growing but EBITDA swung negative in the 1Q21.\nDoughnut brand Krispy Kreme, Inc. plans to raise $600 million at a $3.8 billion market cap. Krispy Kreme is an omni-channel business operating through a network of doughnut shops, partnerships with retailers, and an e-Commerce and delivery business. The company has a long track record and strong brand awareness, though its growth strategy is unproven.\nLegal solutions provider LegalZoom.com, Inc plans to raise $488 million at a $5.3 billion market cap. LegalZoom states that it is a leading online platform for legal and compliance solutions, claiming that 10% of new LLCs and 5% of new corporations in the US were formed via LegalZoom in 2020. Profitable on an EBITDA basis in the 1Q21, the company operates across all 50 states and over 3,000 counties in the US.\nIdentity verification platform Clear Secure, Inc. plans to raise $376 million at a $4.1 billion market cap. Clear Secure's secure identity platform uses to automate the identity verification process, with main offerings including CLEAR Plus, a consumer aviation subscription service, and two mobile apps. As of 5/31/21, Clear Secure's network included 38 airports, 26 sports and entertainment partners, and 67 Health Pass-enabled partners.\nChinese grocery delivery platform Dingdong (Cayman) Limited plans to raise $343 million at a $6.0 billion market cap. With fresh groceries as its core product categories, Dingdong states that it is the fastest growing on-demand e-commerce company in China. Unprofitable with explosive growth, the company had a 10% share of the on-demand e-commerce market by GMV in 2020.\nSaaS solutions provider EverCommerce Inc. plans to raise $325 million at a $3.4 billion market cap. EverCommerce is a leading provider of integrated, vertically-tailored SaaS solutions for service-based SMBs. The company serves over 500,000 customers across three core verticals: Home Services, Health Services, and Fitness & Wellness Services.\nSoftware provider Intapp, Inc. plans to raise $278 million at a $1.9 billion market cap. Intapp provides industry-specific, cloud-based software solutions for the professional and financial services industry globally. The company had over 1,600 clients as of March 31, 2021, and it currently has more than 20 clients with contracts greater than $1 million of ARR.\nOnline manufacturing marketplace Xometry, Inc. plans to raise $275 million at a $1.9 billion market cap. Xometry states that it is a leading AI-enabled marketplace for on-demand manufacturing. Its buyers include businesses ranging from self-funded start-ups to Fortune 100 companies. Since its inception, over 6.0 million parts have been manufactured through Xometry's platform.\nIntegral Ad Science Holding LLC plans to raise $240 million at a $2.5 billion market cap. The company’s technology provides metrics designed to verify that digital ads are served to a real person, viewable on-screen, and appear in a brand-safe and suitable environment in the correct geography. Profitable on an EBIT basis, Integral Ad Science served over 2,000 customers as of 3/31/21.\nPlus-sized women’s apparel brand Torrid Holdings plans to raise $156 million at a $2.1 billion market cap. Torrid is the largest direct-to-consumer brand of women's plus-size apparel and intimates in North America by net sales. The profitable company markets directly to consumers via physical stores and its e-commerce platform, which represented a majority of sales in the 12 months ended 5/1/21.\nAlzheimer’s biotech Acumen Pharmaceuticals, Inc. plans to raise $125 million at a $607 million market cap. The company's lead candidate, ACU193, is a humanized monoclonal antibody that selectively targets amyloid-beta oligomers. ACU193 entered a Phase 1 trial in patients with mild dementia or cognitive impairment due to AD in the 2Q21, with data expected by year end 2022.\nDigital financial services provider AMTD Digital($(HKD)$) plans to raise $120 million at a $1.4 billion market cap. AMTD Digital states that it is the \"fusion reactor\" at the core of the AMTD SpiderNet ecosystem, operating a comprehensive digital solutions platform in Asia. Profitable with explosive growth, the company primarily generates revenue from fees and commissions in two lines of business.\nDrug formulation developer Aerovate Therapeutics($(AVTE)$) plans to raise $100 million at a $325 million market cap. Aerovate's initial focus is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH). The company has completed a Phase 1 study in healthy volunteers and expects to begin a Phase 2b/3 trial in PAH patients in the 2H21.\nNeuromodulation device provider CVRx Inc plans to raise $100 million at a $333 million market cap. CVRx manufactures and markets its minimally invasive neuromodulation solutions on its proprietary BAROSTIM platform. The company's states that its BAROSTEM NEO product is the first and only commercially available neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction.\nBelgium-listed Nyxoah($(NYXH)$) plans to raise $87 million at an $803 million market cap. Nyxoah's lead product is the Genio system, a CE-marked, minimally-invasive hypoglossal neurostimulation therapy for obstructive sleep apnea. The company began generating revenue from Genio in Europe in July 2020 and is currently conducting a pivotal trial designed to support marketing authorization in the US.\n\nIPO Market Snapshot\nThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 6/24/21, the Renaissance IPO Index was up 2.7% year-to-date, while the S&P 500 was up 13.6%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Palantir Technologies (PLTR). The Renaissance International IPO Index was down 1.5% year-to-date, while the ACWX was up 10.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Smoore International and EQT Partners.","news_type":1},"isVote":1,"tweetType":1,"viewCount":316,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114540426,"gmtCreate":1623081913165,"gmtModify":1704195773572,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"Pls comment and like","listText":"Pls comment and like","text":"Pls comment and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/114540426","repostId":"1196162025","repostType":4,"repost":{"id":"1196162025","pubTimestamp":1623049574,"share":"https://ttm.financial/m/news/1196162025?lang=&edition=fundamental","pubTime":"2021-06-07 15:06","market":"us","language":"en","title":"The second-half recovery is underway, and these are the top stocks to own, analysts say","url":"https://stock-news.laohu8.com/highlight/detail?id=1196162025","media":"cnbc","summary":"The reopening is well underway, and this week Wall Street analysts named some of their top ideas as ","content":"<div>\n<p>The reopening is well underway, and this week Wall Street analysts named some of their top ideas as the second half of 2021 nears.Analysts say the time is now for investors to begin taking advantage ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/06/analysts-like-top-stocks-for-the-recovery-match-booking-holdings.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The second-half recovery is underway, and these are the top stocks to own, analysts say</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe second-half recovery is underway, and these are the top stocks to own, analysts say\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 15:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/06/analysts-like-top-stocks-for-the-recovery-match-booking-holdings.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The reopening is well underway, and this week Wall Street analysts named some of their top ideas as the second half of 2021 nears.Analysts say the time is now for investors to begin taking advantage ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/06/analysts-like-top-stocks-for-the-recovery-match-booking-holdings.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BKNG":"Booking Holdings","MTCH":"Match Group, Inc.","SPG":"西蒙地产","AUD":"Audacy Inc.","WMG":"华纳音乐"},"source_url":"https://www.cnbc.com/2021/06/06/analysts-like-top-stocks-for-the-recovery-match-booking-holdings.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1196162025","content_text":"The reopening is well underway, and this week Wall Street analysts named some of their top ideas as the second half of 2021 nears.Analysts say the time is now for investors to begin taking advantage of the economic recovery and the growing number of quality buying opportunities.CNBC Pro combed through the top Wall Street research to find stocks that should bounce back quickly as 2021 rolls on.They include:Audacy,Booking Holdings,Warner Music Group,MatchandSimon.Match GroupThe online dating app company is poised to break out as mobility improves, according to Susquehanna analyst Shyam Patil.“Lots of upside potential still left ahead,” Patil wrote in a recent note.Match, which owns Tinder and several other dating websites, reported a robust earnings report in early may where it beat on revenue.“Tinder is continuing its momentum, and non-Tinder brands are crushing expectations, reaching a new record of 30% y/y growth in 1Q,” he said.Even as shares are down about 8.7% this year and have struggled under the weight of the pandemic, Patil said investors should stick with the stock.“We see MTCH as one of the strongest business franchises in the Internet sector, believe a likely second-half recovery should be a strong tail wind and would recommend taking advantage of the recent dip in the shares,” he wrote.It should be no surprise then, Patil added, that Match revenue continues to accelerate, especially as consumers reenter society.“MTCH noted that momentum is continuing across the portfolio, partially driven by the vaccine rollouts, particularly in the U.S.,” the firm wrote.Simon Property GroupA strong recovery is finally in sight for the beleaguered real estate investment trust and owner of malls and outlet centers, Piper Sandler analyst Alexander Goldfarb wrote in a recent note.The firm raised its price target on Simon to a Street high price target of $150 per share from $130 after the company reported strong first-quarter earnings in May.“All in all, the strong 1Q21 beat and guidance increase, from a team known to be conservative, bodes well for the balance of this year into next,” he said.Additionally, March sales were back to 2019 levels and that should give investors confidence that more foot traffic is just around corner, Goldfarb said.“As the return to normalcy accelerates, we expect the retail landscape to continue its robust rebound, especially into a mask-free 2021 holiday season,” he said.Goldfarb also predicted that consumers may see a familiar face return to Simon malls as it gets closer to December.“This even opens the door for a return of Santa in-person for the holidays, which further showcases the importance of the mall within the consumer landscape,” Goldfarb said.Shares of Simon are up about 55% this year.AudacyInvestors should buy the dip in shares of the broadcast and website radio platform company, Wells Fargo analyst Steven Cahall said in a note to clients.The company, formerly known as Radio.com, is coming off a mixed first-quarter earnings report, but Cahall said he believes local customer spending is finally picking up and in some cases exceeding 2019 levels.“Audacy remains in our 2H recovery bucket as we expect the local ad market will snap back with reopening,” he wrote.A return to growth in the second quarter is also possible, making the stock attractive right now, Cahall said.“There are early signs of pent-up demand in impacted verticals, such as restaurants, retail, and sporting events — and we believe the combination of small- and mid-sized businesses returning, local events coming back and digital revenue growth will drive a strong top line acceleration in 2H21,” he said.The stock is also cheap, according to Cahall, who has Street high price target of $7 per share on Audacy.“We see no reason why reopening won’t happen so the recent pullback presents a nice entry point for this value stock, in our view,” the firm wrote.Shares finished the week down 1.8%.Warner Music Group - Guggenheim, Buy rating“WMG delivered strong F2Q results with double-digit revenue growth at both Recorded Music and Music Publishing. Importantly, the company’s investments in international growth and digital initiatives support our positive long-term view based on unique intellectual property control, leadership position in new content sourcing and increasing exposure to secular growth businesses. Looking forward, we expect continued revenue strength in streaming/digital driven by a strong 2H release slate & expanded partnerships as well as recovery of COVID impacted businesses like live performances.Match - Susquehanna, Positive rating“Upside Potential Still Left Ahead. … We see MTCH as one of the strongest business franchises in the Internet sector, believe a likely 2H recovery should be a strong tailwind, and would recommend taking advantage of the recent dip in the shares. Tinder is continuing its momentum, and non-Tinder brands are crushing expectations, reaching a new record of 30% y/y growth in 1Q. We view the outlook as solid yet conservative and believe MTCH has an opportunity to further accelerate revenue in 2Q. … MTCH noted that momentum is continuing across the portfolio, partially driven by the vaccine rollouts, particularly in the U.S.”Simon Property - Piper Sandler, Overweight rating“As the return to normalcy accelerates, we expect the retail landscape to continue its robust rebound, especially into a mask-free 2021 holiday season. … Notably, sales in March were back up to 2019 levels, and with the change in CDC guidance we expect an increasing number of shoppers will feel comfortable shopping indoors post-vaccine. This even opens the door for a return of Santa in-person for the holidays, which further showcases the importance of the mall within the consumer landscape. … The strong 1Q21 beat and guidance increase, from a team known to be conservative, bodes well for the balance of this year into next.”Audacy - Wells Fargo, Overweight rating“While the local ad recovery has lagged national to begin the year, AUD expects a hockey stick return to growth beginning in 2Q. … We see no reason why reopening won’t happen so the recent pullback presents a nice entry point for this value stock, in our view. … There are early signs of pent-up demand in impacted verticals, such as restaurants, retail, and sporting events — and we believe the combination of SMB’s returning, local events coming back and digital revenue growth will drive a strong top line acceleration in 2H21. … AUD remains in our 2H recovery bucket as we expect the local ad market will snap back with reopening.”Booking Holdings - Wolfe, Outperform rating“BKNG reported mixed 1Q results, as total bookings beat consensus estimates by 19%, while Revenue and EBITDA were 2% and $90m below the Street, respectively. Management discussed improving trends through April, with U.S. hotel room nights above pre-COVID levels, as pent-up consumer demand is expected to drive a strong summer travel rebound. Trends across Europe remain more challenged given lagging vaccination rates but are expected to improve ahead of the summer months. Overall, near term results remain at depressed levels, but demand trends are picking up and hopes of a strong 2H recovery are intact.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":614,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":192214112,"gmtCreate":1621211176436,"gmtModify":1704353902258,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"Like pls.","listText":"Like pls.","text":"Like pls.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/192214112","repostId":"1195301764","repostType":4,"isVote":1,"tweetType":1,"viewCount":171,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161747567,"gmtCreate":1623941963459,"gmtModify":1703824210706,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/161747567","repostId":"1199020816","repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"tweetType":1,"viewCount":364,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184345242,"gmtCreate":1623686362986,"gmtModify":1704208772007,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/184345242","repostId":"2143738859","repostType":4,"repost":{"id":"2143738859","pubTimestamp":1623684317,"share":"https://ttm.financial/m/news/2143738859?lang=&edition=fundamental","pubTime":"2021-06-14 23:25","market":"us","language":"en","title":"Vaccine Stocks Slide After Novavax Shot Proves Highly Effective","url":"https://stock-news.laohu8.com/highlight/detail?id=2143738859","media":"Bloomberg","summary":"(Bloomberg) -- The world’s top makers of Covid-19 vaccines are dropping after tests of Novavax Inc.’","content":"<p>(Bloomberg) -- The world’s top makers of Covid-19 vaccines are dropping after tests of Novavax Inc.’s shots showed they were 90% effective at preventing symptoms.</p>\n<p>Stocks tied to inoculations already cleared for emergency use fell in Monday’s trading, led by Moderna Inc.’s slide of as much as 9.5%. Pfizer Inc. fell 1.6% and the drugmaker’s German partner <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> dropped 6.1%. Even the consumer giant Johnson &amp; Johnson slipped 0.6%, slightly more than the S&amp;P 500 index as the broader market dropped back from Friday’s record highs.</p>\n<p>Novavax itself wasn’t immune from the downdraft it created, with the stock reversing a 9.5% gain on Monday to fall about 1%. The shot’s efficacy was better than Wall Street was expecting amid the spread of more resistant variants, and that’s raising the specter of new competition. Novavax now has “a viable alternative to mRNA vaccines,” like Pfizer and BioNTech or Moderna’s shots, an analyst at Jefferies said.</p>\n<p>But with Novavax up 91% so far this year and after a more than 2,700% leap in 2020, it wasn’t enough to further bolster shares. Biotech stocks often climb ahead of highly watched catalyst, only to give back gains even after a positive update.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Stocks Slide After Novavax Shot Proves Highly Effective</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Stocks Slide After Novavax Shot Proves Highly Effective\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 23:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/vaccine-stocks-slide-novavax-shot-145617752.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- The world’s top makers of Covid-19 vaccines are dropping after tests of Novavax Inc.’s shots showed they were 90% effective at preventing symptoms.\nStocks tied to inoculations already ...</p>\n\n<a href=\"https://finance.yahoo.com/news/vaccine-stocks-slide-novavax-shot-145617752.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc.","PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/vaccine-stocks-slide-novavax-shot-145617752.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143738859","content_text":"(Bloomberg) -- The world’s top makers of Covid-19 vaccines are dropping after tests of Novavax Inc.’s shots showed they were 90% effective at preventing symptoms.\nStocks tied to inoculations already cleared for emergency use fell in Monday’s trading, led by Moderna Inc.’s slide of as much as 9.5%. Pfizer Inc. fell 1.6% and the drugmaker’s German partner BioNTech SE dropped 6.1%. Even the consumer giant Johnson & Johnson slipped 0.6%, slightly more than the S&P 500 index as the broader market dropped back from Friday’s record highs.\nNovavax itself wasn’t immune from the downdraft it created, with the stock reversing a 9.5% gain on Monday to fall about 1%. The shot’s efficacy was better than Wall Street was expecting amid the spread of more resistant variants, and that’s raising the specter of new competition. Novavax now has “a viable alternative to mRNA vaccines,” like Pfizer and BioNTech or Moderna’s shots, an analyst at Jefferies said.\nBut with Novavax up 91% so far this year and after a more than 2,700% leap in 2020, it wasn’t enough to further bolster shares. Biotech stocks often climb ahead of highly watched catalyst, only to give back gains even after a positive update.","news_type":1},"isVote":1,"tweetType":1,"viewCount":279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151189940,"gmtCreate":1625067450680,"gmtModify":1703735433736,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"Comment and like","listText":"Comment and like","text":"Comment and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/151189940","repostId":"2147146918","repostType":4,"isVote":1,"tweetType":1,"viewCount":325,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098167250,"gmtCreate":1644049860495,"gmtModify":1676533886439,"author":{"id":"3564454055125110","authorId":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3564454055125110","authorIdStr":"3564454055125110"},"themes":[],"htmlText":"$sofi&nbsp;","listText":"$sofi&nbsp;","text":"$sofi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098167250","isVote":1,"tweetType":1,"viewCount":133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}